Characterization of direct and/or indirect genetic associations for multiple traits in
longitudinal studies of disease progression

Myriam Brossard,[*,1] Andrew D. Paterson,[†,‡] Osvaldo Espin-Garcia,[‡,**,§§] Radu V. Craiu,[**] Shelley
B. Bull[*,‡,1]

[*]Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, M5T 3L9, Ontario, Canada;
[†]Program in Genetics and Genome Biology, Hospital for Sick Children Research Institute, M5G
1X8, Toronto, Ontario, Canada;
[‡]Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, M5T 3M7,
Toronto, Ontario, Canada;
[§]Department of Biostatistics, Princess Margaret Cancer Centre, M5G 2C1, Toronto, Ontario,
Canada;
[**]Department of Statistical Sciences, University of Toronto, M5S 3G3, Toronto, Ontario, Canada;
[§§]Department of Epidemiology and Biostatistics, Western University, N6A 5C1, London, Ontario,
Canada.

Abstract

When quantitative longitudinal traits are risk factors for disease progression and subject to random
biological variation, joint model analysis of time-to-event and longitudinal traits can effectively
identify direct and/or indirect genetic association of single nucleotide polymorphisms (SNPs) with
time-to-event. We present a joint model that integrates: *i)* a multivariate linear mixed model
describing trajectories of multiple longitudinal traits as a function of time, SNP effects, and
subject-specific random effects, and *ii)* a frailty Cox survival model that depends on SNPs,
longitudinal trajectory effects, and subject-specific frailty accounting for dependence among
multiple time-to-event traits. Motivated by complex genetic architecture of type 1 diabetes
complications (T1DC) observed in the Diabetes Control and Complications Trial (DCCT), we
implement a two-stage approach to inference with bootstrap joint covariance estimation and
develop a hypothesis testing procedure to classify direct and/or indirect SNP association with each
time-to-event trait. By realistic simulation study, we show that joint modelling of two time-to-
T1DC (retinopathy, nephropathy) and two longitudinal risk factors (HbA1c, systolic blood
pressure) reduces estimation bias in genetic effects and improves classification accuracy of direct
and/or indirect SNP associations, compared to methods that ignore within-subject risk factor
variability and dependence among longitudinal and time-to-event traits. Through DCCT data
analysis, we demonstrate feasibility for candidate SNP modelling, and quantify effects of sample
size and Winner's curse bias on classification for two SNPs identified as having indirect
associations with time-to-T1DC traits. Overall, joint analysis of multiple longitudinal and multiple
time-to-event traits provides insight into complex trait architecture.

Running title: **Joint models for multiple-trait genetics**.

Key words: joint models; longitudinal study; direct and/or indirect genetic association; pleiotropy;

complex genetic architecture; multiple-trait analysis; random measurement error; quantitative trait

trajectory; mixed model; frailty model.

[1]**Corresponding authors:** Lunenfeld-Tanenbaum Research Institute, 60 Murray Street, Box #18,

M5T 3L9, Toronto, Ontario, Canada. E-mails: bull@lunenfeld.ca, brossard@lunenfeld.ca. Phone

number: +1 416-586-5052.

INTRODUCTION

Despite their known ability to improve inference in clinical and epidemiological studies, particularly in the presence of informative censoring/dropout or when longitudinal traits are measured with biological random variation (Hogan and Laird 1998; Ibrahim et al. 2010; Chen et al. 2011), joint models for longitudinal and time-to-event (TTE) outcomes have received limited attention in genetic association study design and analysis. Genome-wide association studies (GWAS) of quantitative traits (QTs) often require follow-up analyses to identify whether SNP associations detected with each of the QT(s), analyzed separately, also affect related disease outcomes through direct and/or indirect effects induced by those QTs (Fig. 1). Such QTs can include established intermediate risk factors for clinical outcomes, which may be measured with high within-subject variability (e.g. random biological variation). By accounting for random measurement error in intermediate QT risk factors and dependencies among traits, joint model analysis can improve accuracy and efficiency of effect estimation, as well as detection and interpretation of SNP associations.

The multiple-trait extensions we develop stem from a random-effects joint model that consists of a sub-model for a single longitudinal trait linked to a sub-model for a single right-censored time-to-event trait (Wu et al. 2012; Asar et al. 2015). The longitudinal sub-model describes the QT as an underlying smooth trajectory that depends on fixed effects of time and baseline covariates, as well as subject-specific random effects. The joint model association structure is induced via the functional dependence between the hazard of an event at time t and the longitudinal trait trajectory (Hickey et al. 2016; Papageorgiou et al. 2019). Specification of this relationship can be based on prior biological knowledge of the link between the longitudinal and time-to-event traits. As previously elucidated, this class of joint models provides interpretations of direct and/or indirect

effects because the relationship between a baseline covariate, such as a SNP genotype, and each

of the longitudinal and time-to-event traits, as well as the relationship between the longitudinal

and time-to-event traits can be specified via model parameters corresponding to direct, indirect

and overall effects (Ibrahim et al. 2010). In this report, we demonstrate that extensions to jointly

model multiple longitudinal and multiple time-to-event traits can further improve inference by *(i)*

borrowing information shared among correlated traits, and *(ii)* accounting for indirect genetic

pathways from multiple longitudinal QT risk factors, that if ignored, can confound an indirect

genetic association with a direct association.

Joint model extensions have been reviewed for multiple longitudinal traits (Hickey et al. 2016;

Papageorgiou et al. 2019) and for multiple time-to-event traits (Hickey et al. 2018a). Although a

few extensions have been developed for both multiple longitudinal and multiple time-to-event

traits, for example (Zhu et al. 2012; Tang et al. 2014; Tang and Tang 2014), these models are often

formulated for a specific study question, and thus can lack generalizability. In addition, such

extensions raise computational challenges for maximisation of the marginal likelihood that

integrates over the distribution of the multivariate random effects. Two-stage approaches for joint

model fitting are computationally efficient and allow more flexible model formulations (Self and

Pawitan 1992; Tsiatis et al. 1995; Bycott and Taylor 1998; Dafni and Tsiatis 1998). However, in

some circumstances, inference can be mis-calibrated when parameter estimates and predictions

from Stage 1 are obtained from the longitudinal model without consideration of the time-to-event

outcome, or when the uncertainty in Stage 1 estimates is ignored during Stage 2 estimation

(Wulfsohn and Tsiatis 1997), a problem known as propagation of errors.

Motivated by the complex genetic architecture of long-term type 1 diabetes complications (T1DC),

we develop a joint-model extension to evaluate genetic associations with multiple longitudinal QT

risk factors and multiple TTE traits. Risk of development of T1DC, including diabetic retinopathy

(DR) and diabetic nephropathy (DN), is hypothesized to result from multiple genetic factors with

potential direct and/or indirect effects induced via multiple shared and/or specific QT risk factors

(Paterson and Bull 2012). Besides potential genetic factors, hyperglycemia (measured by

Hemoglobin A1c, hereafter abbreviated as HbA1c) represents a major risk factor for T1DC;

intensive insulin therapy to control the HbA1c level to a normal range prevents and delays

progression of long-term T1DC, as demonstrated by the Diabetes Control and Complications Trial

(DCCT, (The Diabetes Control and Complications Trial Research Group 1993)). The first GWAS

to analyze the DCCT study phenotypes identified two SNPs associated with within-patient mean

HbA1c at genome-wide significance in the Conventional treatment arm, namely rs10810632 (in

BNC2, 9p22.2) and rs1358030 (near *SORCS1,* 10q25.1), and reported weaker SNP associations

with the secondary outcomes time-to-DR and/or time-to-DN (Paterson et al. 2010). Genetic

association studies also reported variants with potential pleiotropic effects on DR and DN

(Hosseini et al. 2015). Other measured longitudinal QTs, also influenced by genetic factors, are

postulated to have associations with T1DC, for example, association of systolic blood pressure

(SBP) with DN.

Our objective is to develop an integrated approach to investigate the complex genetic architecture

of disease complications, and associated risk factors, as in the motivating study of type 1 diabetes

complications. The approach we develop entails multiple longitudinal risk factors and multiple

time-to-event outcomes, as well as multiple SNP associations with multiple traits. In addition to

genetic variants associated with risk factors, the model needs to handle multiple longitudinal

quantitative risk factors that can be related to more than one complication, and genetic variants

that can affect risk of more than one complication directly and/or indirectly through intermediate

risk factor(s); accounting for known intermediate longitudinal QTs is essential to correctly

distinguish between direct and indirect genetic effects on each T1DC trait. To this end, we

formulate a general model extension to multiple longitudinal QTs and multiple TTE traits, which

proposes correlated random effects and a frailty term to address dependency among QTs and

among TTE traits.

Based on the DCCT study, we hypothesize a multi-trait model for T1DC genetic architecture, and

develop methods to investigate it. Because the goal of intensive therapy in DCCT was to reduce

HbA1c into the non-diabetic range, which produced treatment differences in HbA1c values, we

base our joint model evaluation and application on N=667 unrelated individuals of European

ancestry from the Conventional treatment group. Longitudinal measurements for HbA1c and SBP

were recorded irrespective of the occurrence of any complication event(s) at up to 39 quarterly

visits (See File S1 for a description of the DCCT dataset we analysed). HbA1c and SBP are

established risk factors for T1DC, and genetic association with either risk factor can induce an

indirect genetic association with T1DC. The latter can be mistaken as a direct genetic association

when the intermediate longitudinal risk factor(s) is ignored. Distinguishing between direct and/or

indirect genetic effects can help to reveal genetic pathways in the aetiology of T1DC with

implications for the direction of on-going investigations, and development of new intervention

strategies. Nevertheless, accurate classification of direct and/or indirect SNP associations is

challenged by within-patient variability in intermediate QT(s), and unmeasured shared risk factors

among longitudinal and time-to-event traits.

The *primary* contribution of our work is a general formulation of a joint model for multiple

longitudinal QT risk factors and multiple time-to-event traits in genetic association studies. We

develop inference methods for statistical genetic analysis using a two-stage approach to joint

model parameter estimation and hypothesis testing, including a procedure to classify SNP

associations with each time-to-event trait as direct and/or indirect. A *second* contribution of this

paper is the development of a data-informed simulation algorithm, under the postulated multi-trait

model for T1DC genetic architecture, to generate multiple causal SNPs with various direct effects

on simulated TTE traits and/or indirect effects via observed (measured) longitudinal QTs in DCCT

and unobserved (simulated) longitudinal QTs. This algorithm provides a general approach to

estimate power of the joint modeling approach (in comparison to alternative methods) given study

sample size and various direct/indirect genetic associations via observed or unobserved

longitudinal QT(s) risk factors for time to disease complications. Our numerical investigations

show that the proposed method reduces estimation bias and improves accuracy of classification of

direct and/or indirect SNP associations in comparison with separate joint models for each pair of

longitudinal QT and time-to-event trait, and approaches that ignore measurement error in

longitudinal QT(s). *Lastly*, we show computational feasibility and interpretation in an extended

joint model application to DCCT genetic association analyses of candidate SNPs. Using the

proposed procedure, we classify rs10810632 and rs1358030 as having indirect association with

two T1DC traits via the HbA1c longitudinal risk factor, and obtain similar conclusions using

alternative time-dependent association structures that account for cumulative and time-weighted

effects of HbA1c on T1DC traits (Lind et al. 1995; Lind et al. 2010). Example programs written

in R for data simulation and for application of the proposed joint model are available on GitHub.

                                   MATERIALS AND METHODS

Model Formulation

We assume that a set of M SNPs have been genotyped, together with observation of K ($1 \leq k \leq K$)

unordered and non-competing time-to-event traits, such as multiple disease complications, and L

($1 \leq l \leq L$) longitudinal QTs (*i.e.* intermediate risk factors) measured in N unrelated individuals

indexed by i ($1 \leq i \leq N$). To characterize the genetic architecture of multiple longitudinal risk

factors and multiple time-to-events, we formulate a shared-random-effects joint model that

connects longitudinal and time-to-event sub-models through specified time-dependent association

structures. For ease of presentation, we simplify the model notation by assuming no adjusting

covariates but note that trait-specific and/or shared covariates, such as confounding factors or

ancestry-related principal components can be easily incorporated. We first introduce the joint

model for one longitudinal trait ($L = 1$) and one time-to-event trait ($K = 1$). Then, in the

subsequent subsection, we present the extension for an arbitrary number of longitudinal and time-

to-event traits.

Joint model for *one* longitudinal and *one* time-to-event trait – For each individual i, we define

$\boldsymbol{y_i} = (y_{i,1}, \ldots, y_{i,j}, \ldots, y_{i,J})$, as the vector of QT measures collected over the J visit times $\boldsymbol{t_i} =$

$(t_{i,1}, \ldots, t_{i,j}, \ldots, t_{i,J})^T$ with $1 \leq j \leq J$ and $t_{i,1} \leq \cdots \leq t_{i,j} \leq \cdots \leq t_{i,J}$. We denote (T_i, δ_i) as the

vector of right-censored event time T_i and event indicator δ_i for the time-to-event trait, and assume

$T_i = \min(T_i^*, C_i)$, where T_i^* is the latent (uncensored) event time and C_i is the censoring time (e.g.,

administrative censoring). We define $\delta_i = I(T_i^* \leq C_i)$, with $\delta_i = 1$ if the event occurs during the

observation period, and $\delta_i = 0$ otherwise.

Longitudinal sub-model. This is specified by a mixed-effects model for the longitudinal QT, based

on the (Laird and Ware 1982) linear mixed model. The model builds on the assumption that for

every individual in the sample there exists an underlying smooth trajectory of the longitudinal QT

that describes the subject-specific evolution dependent on time, SNP effect, and individual-level

random effects $\boldsymbol{b_i}$. To simplify the presentation, we assume a linear QT trajectory (Equation 1),

but the longitudinal sub-model can be adapted for nonlinear trajectories using, for example, higher

order polynomials or splines (Rizopoulos 2012):

$$y_i^*(t) = \beta_0 + b_{i,0} + (\beta_1 + b_{i,1})t + \beta_g g_i \qquad \text{(Equation 1, smooth linear trajectory)}$$

Where:

- g_i, is the genotype of the individual i for the SNP being tested, coded as the number of

copies of the minor allele,

- $\boldsymbol{\beta} = (\beta_0, \beta_1, \beta_g)^T$ is the vector of fixed intercept and slope time effects and fixed genetic

effect on the longitudinal QT,

- $\boldsymbol{b_i} = (b_{i,0}, b_{i,1})^T$ are the subject-specific random intercept and slope time effects assuming

$\boldsymbol{b_i} \sim N_2(0, \boldsymbol{D})$ and $\boldsymbol{D}$ is the variance-covariance matrix.

This trajectory cannot be observed directly, rather we observe longitudinal measurements $\boldsymbol{y_i}$

collected at discrete time points $\boldsymbol{t_i}$; measurements are subject to independent and identically

distributed noise contamination variables $\boldsymbol{\varepsilon_i} \sim N_J(0, \boldsymbol{\Sigma})$, where $\boldsymbol{\varepsilon_i} = (\varepsilon_{i,1}, \dots, \varepsilon_{i,j}, \dots, \varepsilon_{i,J})^T$, $\boldsymbol{\Sigma} =$

$\sigma^2 \boldsymbol{I_J}$, with σ^2, the residual variance of the QT:

$\boldsymbol{y}_i = y_i^*(\boldsymbol{t}_i) + \boldsymbol{\varepsilon}_i$ (Equation 2, vector of observed trait values)

We assume that $\boldsymbol{b}_i$ and $\boldsymbol{\varepsilon}_i$ are independent (Laird and Ware 1982).

Equation 2 implies that $\boldsymbol{y}_i$ in $\mathfrak{R}^J$ follows a multivariate normal distribution with:

$E[\boldsymbol{y}_i] = \boldsymbol{X}_i\boldsymbol{\beta}$ and $Var[\boldsymbol{y}_i] = \boldsymbol{Z}_i\boldsymbol{D}\boldsymbol{Z}_i^T + \boldsymbol{\Sigma},$

where $\boldsymbol{X}_i = \left(\boldsymbol{1}_J, \boldsymbol{t}_i, g_i\boldsymbol{1}_J\right)$ denotes the (J-by-3) design matrix for the fixed intercept, slope, and

SNP effects, and $\boldsymbol{Z}_i = \left(\boldsymbol{1}_J, \boldsymbol{t}_i\right)$ is the (J-by-2) design matrix for the random intercept and slope

effects, with $\boldsymbol{1}_J = (1, \dots, 1, \dots, 1)^T$. To increase robustness to misspecification of the variance-

covariance matrix $\boldsymbol{D}$, we adopt an unstructured form for the random-effects variance, defined as

$\boldsymbol{D} = \begin{pmatrix} \mathrm{Var}(b_{i,0}) & \mathrm{Cov}(b_{i,0}, b_{i,1}) \\ \mathrm{Cov}(b_{i,0}, b_{i,1}) & \mathrm{Var}(b_{i,1}) \end{pmatrix}$, with the added benefit of not requiring additional

constraints on the serial dependence between the repeated measurements for each individual. This

choice implies that the covariance function between any pair of QT observations for individual i

collected at two distinct visit times $t_{i,j} \neq t_{i,s}$ ($1 \leq j \leq J$ and $1 \leq s \leq J$, with $j \neq s$) is given by

$Cov(y_{i,j}, y_{i,s}) = t_{i,j}t_{i,s}Var(b_{i,1}) + (t_{i,j} + t_{i,s})Cov(b_{i,0}, b_{i,1}) + Var(b_{i,0}) + \sigma^2$, with variance

function $Var(y_{i,j}) = t_{i,j}^2 Var(b_{i,1}) + 2t_{i,j}Cov(b_{i,0}, b_{i,1}) + Var(b_{i,0}) + \sigma^2$, which is quadratic

over time with positive curvature at $Var(b_{i,1})$.

Time-to-event sub-model. This is specified by a proportional hazards model (PH model), in which

the hazard function of the time-to-event trait is defined as the instantaneous event rate in a small

interval around T_i^* given that the event has not occurred before time t, genetic effect and a function

of the history of the true unobserved longitudinal process up to time t that is associated with risk

of the event, $W_i(t) = f(Y_i^*(t))$, with $Y_i^*(t) = \{y_i^*(s), 0 \le s \le t\}$. We specify that the hazard

function (Equation 3) depends on the SNP effect adjusted for association of the longitudinal QT

risk factor with the time-to-event trait.

Now, $\lambda_i(t) = \lim\limits_{dt \to 0} \Pr\{t \le T_i^* < t + dt \mid T_i^* \ge t,\ W_i(t) = f(Y_i^*(t)),\ g_i\}/dt$

217   and we assume $\lambda_i(t) = \lambda_0(t) \times exp\{\alpha w_i(t) + \gamma_g g_i\}$ (Equation 3)

218   Where:

219   • $\lambda_0(t)$ is a (parametric or non-parametric) baseline hazard function;

220   • $w_i(t) = f(y_i^*(t))$ specifies the function of the longitudinal QT trajectory accounting for

221   trajectory values at time t that is associated with risk of the event. In the case of a

222   *contemporaneous* parametrization, the hazard of an event at a time t depends on the

223   longitudinal trajectory value at the same time t (*i.e.* $w_i(t) = y_i^*(t)$). Other functional forms

224   of the QT trajectory can weight earlier QT values according to prior knowledge of the

225   relationship of the QT with the time-to-event trait (Hickey et al. 2016; Mauff et al. 2017;

226   Papageorgiou et al. 2019);

227   • α is the effect of the longitudinal QT risk factor on the time-to-event trait;

228   • γ_g denotes the genetic effect on the time-to-event trait accounting for association of the

229   longitudinal QT risk factor with the time-to-event trait.

Interpretation. As depicted in Fig. 1, the joint model parameters characterize relationships among

a SNP, an intermediate QT, and a time-to-event trait and decompose possible effects of a SNP on

a time-to-event trait into: an indirect effect induced via the SNP effect on the longitudinal QT; and

a direct SNP effect independent of the QT (Ibrahim et al. 2010; Hickey et al. 2018b).

Based on the SNP effects, β_g and γ_g, and assuming $\alpha \neq 0$, a SNP association with a time-to-event

trait can be one of three types:

- indirect SNP association: the SNP has a non-null effect on the longitudinal QT ($\beta_g \neq 0$), but no effect on the time-to-event trait ($\gamma_g = 0$); the overall SNP effect θ depends on the indirect effect ($\theta = \mu_g$, with $\mu_g = \alpha\beta_g$).

- direct SNP association: the SNP has a non-null effect on the time-to-event trait ($\gamma_g \neq 0$), but no effect on the longitudinal QT ($\beta_g = 0$); the overall SNP effect depends only on the direct effect ($\theta = \gamma_g$).

- both direct and indirect SNP associations: the SNP has non-null effects on the longitudinal risk factor ($\beta_g \neq 0$) and on the time-to-event trait ($\gamma_g \neq 0$). In this case, the overall SNP effect θ aggregates the indirect and direct SNP effects ($\theta = \mu_g + \gamma_g$, with $\mu_g = \alpha\beta_g$).

In later subsections, we detail statistical implementation for estimation of the α, β_g and γ_g

parameters and associated hypothesis testing in the joint model, which underlie the procedure we

then propose to classify the SNP association as indirect, direct, or both direct and indirect.

When an associated longitudinal risk factor is omitted from the time-to-event model, the estimated

SNP effect on the time-to-event trait captures the overall SNP effect $\left(\theta = \mu_g + \gamma_g\right)$. This can

occur in GWAS when the time-to-event analysis ignores an intermediate risk factor or when the

time-to-event trait is associated with more than one intermediate risk factor. This observation also

illustrates one of the limitations of the joint model for *one* longitudinal with *one* time-to-event trait,

with the consequence that an indirect SNP association can be mistaken as a direct association when

other longitudinal risk factors are omitted in the joint model.

Generalization of the joint model to *multiple* longitudinal and *multiple* time-to-event traits –

To characterize the genetic architecture of a system of multiple longitudinal risk factors and

multiple time-to-events, we propose an extension of the joint model to L longitudinal and K time-

to-event traits ($L>1$, $K>1$), as shown in Fig. 2 and detailed as follows. We define $\boldsymbol{y_{i,l}} =$

$(y_{i,l,1}, \dots, y_{i,l,j}, \dots, y_{i,l,J})$ as the observed longitudinal measures for each lth QT, $1 \le l \le L$, collected

over the J visit times $\boldsymbol{t_i}$. We define $(T_{i,k}, \delta_{i,k})$ as the vector of observed right-censored event time

$T_{i,k}$ and event indicator $\delta_{i,k}$ for each kth time-to-event trait for individual i, with $\delta_{i,k} = I(T_{i,k}^* \le$

$C_i)$. We assume the same censoring time C_i across all K outcomes, but the model can be extended

to situations where C_i varies for each time-to-event trait. Again, for ease of presentation, we

simplify the model notation with no adjusting covariates and assume linear trajectories for all L

longitudinal traits and contemporaneous effects of L longitudinal traits on the K time-to-event

traits. The model can be extended to account for non-linear trajectories, cumulative longitudinal

effects, and trait-specific and/or shared covariates such as confounding factors or ancestry-related

principal components.

Multivariate longitudinal sub-model. In the extension of the longitudinal sub-model to L

longitudinal traits, we index subscripts in Equations 1 and 2 for each lth longitudinal trait

(Equations 4 and 5 in Fig 2). The vector of observed trait values becomes:

$$\boldsymbol{y_{i,l}} = \boldsymbol{X_{i,l}\beta_l} + \boldsymbol{Z_i b_{i,l}} + \boldsymbol{\varepsilon_{i,l}} \qquad \text{(\textit{observed} repeated measures for the } l^{\text{th}} \text{ QT)}$$

Where:

• $X_{i,l} = (\mathbf{1}_J, t_i, g_i \mathbf{1}_J)$ and $Z_{i,l} = (\mathbf{1}_J, t_i)$ are the design matrices for fixed and random

effects,

• $\boldsymbol{\beta}_l = (\beta_{0,l}, \beta_{1,l}, \beta_{g,l})^T$ and $\boldsymbol{b}_{i,l} = (b_{i,0,l}, b_{i,1,l})^T$ denote the QT-specific fixed and random

effects,

• $\boldsymbol{\varepsilon}_{i,l} = (\varepsilon_{i,1,l}, \dots, \varepsilon_{i,j,l}, \dots, \varepsilon_{i,J,l})^T$ is the vector of residual error terms, with $\boldsymbol{\varepsilon}_{i,l} \sim N_J(\mathbf{0}, \boldsymbol{\Sigma}_l)$,

where $\boldsymbol{\Sigma}_l = \sigma_l^2 \boldsymbol{I}_J$ with σ_l^2, the residual variance for the lth QT; we assume the $\boldsymbol{\varepsilon}_{i,l}$ are

independent for all L traits.

To account for dependence among the L longitudinal QTs, we assume the overall random effects

vector for all L QTs, $\boldsymbol{b}_i = (\boldsymbol{b}_{i,1}, \dots, \boldsymbol{b}_{i,l}, \dots, \boldsymbol{b}_{i,L})^T \sim N_{2L}(\mathbf{0}, \boldsymbol{D})$, where $\boldsymbol{D} = \begin{pmatrix} \boldsymbol{D}_{1,1} & \cdots & \boldsymbol{D}_{1,L} \\ \vdots & \boldsymbol{D}_{l,l} & \vdots \\ \boldsymbol{D}_{L,1} & \cdots & \boldsymbol{D}_{L,L} \end{pmatrix}$ is

the variance-covariance matrix for all L QTs, accounting for serial dependencies within each lth

QT, i.e. $\boldsymbol{D}_{l,l} = \begin{pmatrix} \mathrm{Var}(b_{i,0,l}) & \mathrm{Cov}(b_{i,0,l}, b_{i,1,l}) \\ \mathrm{Cov}(b_{i,0,l}, b_{i,1,l}) & \mathrm{Var}(b_{i,1,l}) \end{pmatrix}$, and accounting for cross-dependencies

between each pair l, m of QTs with $l \neq m$, that is $\boldsymbol{D}_{l,m} = \begin{pmatrix} \mathrm{Cov}(b_{i,0,l}, b_{i,0,m}) & \mathrm{Cov}(b_{i,0,l}, b_{i,1,m}) \\ \mathrm{Cov}(b_{i,1,l}, b_{i,0,m}) & \mathrm{Cov}(b_{i,1,l}, b_{i,1,m}) \end{pmatrix}$.

This formulation implies that the vector of stacked repeated measures for all L longitudinal QTs

for individual i, $\boldsymbol{y}_i = (\boldsymbol{y}_{i,1}, \dots, \boldsymbol{y}_{i,l}, \dots, \boldsymbol{y}_{i,L})^T$ in $\mathfrak{R}^{J \times L}$ follows a multivariate normal distribution

with mean $E[\boldsymbol{y}_i] = \boldsymbol{X}_i \boldsymbol{\beta}$ and variance $Var[\boldsymbol{y}_i] = \boldsymbol{Z}_i \boldsymbol{D} \boldsymbol{Z}_i^T + \boldsymbol{\Sigma}$, where:

• $\boldsymbol{X}_i = diag(\boldsymbol{X}_{i,1}, \dots, \boldsymbol{X}_{i,l}, \dots, \boldsymbol{X}_{i,L})$ and $\boldsymbol{Z}_i = diag(\boldsymbol{Z}_{i,1}, \dots, \boldsymbol{Z}_{i,l}, \dots, \boldsymbol{Z}_{i,L})$ are the

overall (JL-by-$3L$) and (JL-by-$2L$) design block diagonal matrices for the fixed and

random effects respectively;

• $\boldsymbol{\beta} = (\boldsymbol{\beta}_1, \dots, \boldsymbol{\beta}_l, \dots, \boldsymbol{\beta}_L)^T$ is the $3L$-length stacked vector of fixed effects,

• $\boldsymbol{D}$ is the (2L-by-2L) covariance matrix for random effects $\boldsymbol{b_i} = \left(\boldsymbol{b_{i,1}}, \dots, \boldsymbol{b_{i,l}}, \dots, \boldsymbol{b_{i,L}}\right)^T$,

• $\boldsymbol{\Sigma} = diag(\boldsymbol{\Sigma_1}, \dots, \boldsymbol{\Sigma_l}, \dots, \boldsymbol{\Sigma_L})^T$ is the (JL-by-JL) block diagonal matrix of residual

variances.

Assuming, for each lth QT, an unstructured variance-covariance matrix $\boldsymbol{D_{l,l}}$, the variance at each

visit time $t_{i,j}$ is $Var(y_{i,j,l})$ and the covariance function $Cov(y_{i,j,l}, y_{i,s,l})$ between two visit times

$t_{i,j} \neq t_{i,s}$ are analogous to those defined above for the joint model with a single longitudinal and

single time-to-event trait. The multivariate mixed model accounts for dependencies between each

QT pair $l \neq m$ via random-effect covariance functions in the $\boldsymbol{D_{l,m}}$ matrices where the covariance

between observations of two QTs (l, m; $l \neq$ m) measured at the same visit time $t_{i,j}$ is

$Cov(y_{i,j,l}, y_{i,j,m}) = t_{i,j}^2 Cov(b_{i,1,l}, b_{i,1,m}) + t_{i,j}\left(Cov(b_{i,0,l}, b_{i,1,m}) + Cov(b_{i,0,m}, b_{i,1,l})\right) +$

$Cov(b_{i,0,l}, b_{i,0,m})$ which is quadratic over time, and the covariance function between two

longitudinal QTs ($l \neq m$) measured at different visit times $t_{i,j} \neq t_{i,s}$ is $Cov(y_{i,j,l}, y_{i,s,m}) =$

$t_{i,j} t_{i,s} Cov(b_{i,1,l}, b_{i,1,m}) + t_{i,j} Cov(b_{i,1,l}, b_{i,0,m}) + t_{i,s} Cov(b_{i,0,l}, b_{i,1,m}) + Cov(b_{i,0,l}, b_{i,0,m})$. Thus,

joint analysis of correlated longitudinal QTs is expected to improve power over separate analysis

of each QT by borrowing information through implied dependency structures among the random

effects.

Multivariate time-to-event sub-model. Finally, we extend Equation 3 to a multivariate PH frailty

time-to-event sub-model, with a subject-specific random effect (frailty term, u_i) introduced to

capture potential unexplained dependencies (e.g. due to unmeasured baseline shared factors)

among the time-to-event traits. In Equation 6 (Fig 2), $\lambda_{0,k}(t)$ and $\gamma_{g,k}$, correspond to the baseline

hazard function, and SNP effect on the kth time-to-event trait ($1 \leq k \leq K$), accounting for association

of each lth QT with the time-to-event trait k ($\alpha_{l,k}, 1 \leq l \leq L$). We assume that the subject-

specific frailty term follows a gamma distribution, that is $u_i \sim \Gamma(a, b)$ with a, $b>0$, and represents

dependencies among the K traits. Equation 6 (Fig 2) can be expressed as:

318
$$\lambda_{i,k}(t) = \lambda_{0,k}(t) \times exp\{\boldsymbol{\alpha_k} \boldsymbol{w_{i,k}}(t) + \gamma_{g,k} g_i + u_i\},$$

where $\boldsymbol{\alpha_k} = (\alpha_{1,k}, \dots, \alpha_{l,k}, \dots, \alpha_{L,k})^T$ is the vector of all L QT effects on the kth time-to-event trait,

and $\boldsymbol{w_{i,k}}(t) = \left(w_{i,1,k}(t), \dots, w_{i,l,k}(t), \dots, w_{i,L,k}(t)\right)$ specifies the corresponding association

profile of each QT with the kth time-to-event trait. We note $w_{i,l,k}(t) = f_{l,k}\left(y_{i,l}^*(t)\right)$, where

$y_{i,l}^*(t)$, denotes the lth QT trajectory ($1 \leq l \leq L$) at time t, which depends on the fixed and random

effects $\boldsymbol{\beta_l}$ and $\boldsymbol{b_{i,l}}$.

Comparisons with joint model of one longitudinal and one time-to-event trait. In the proposed

joint model extension for multiple longitudinal and multiple time-to-event traits, the direct, indirect

and overall SNP effects defined above for the joint model with one longitudinal and one time-to-

event trait are interpreted similarly. However, there are important practical differences between

the latter model for a pair of traits and the proposed multi-trait. *First*, because the joint model

extension can account for multiple intermediate longitudinal QT risk factors associated with one

(or multiple) time-to-event trait(s), it improves-inference for SNP association and accuracy of SNP

classification, particularly when a time-to-event trait depends on more than one longitudinal risk

factor as illustrated in our numerical experiments. *Second,* in the multivariate longitudinal sub-

model, the variance-covariance matrix $\boldsymbol{D}$ for the random effects specifies non-null covariance

terms in $\boldsymbol{D_{l,m}}$ for each pair of longitudinal QT l, m ($1 \leq l \leq L$ and $1 \leq m \leq L$, $l \neq m$). In

contrast, under the assumption of null covariance terms in $\boldsymbol{D_{l,m}}$ for all QT pairs inherent in separate

analyses of each QT, the multivariate sub-model reduces to independent sub-models for each

longitudinal QT. When longitudinal QTs are correlated, assuming null covariances can fail to make

use of information borrowed through the random effects and reduce efficiency of the parameter

estimates in the longitudinal trajectories (Shah et al. 1997; Jensen and Ritz 2018). This, in turn,

can affect estimation in the time-to-event model. *Third*, without a frailty term u_i, the time-to-event

sub-model (Equations 6 and 7) reduces to separate time-to-event sub-models for each time-to-

event trait. *Thus*, through use of a shared frailty term, the extended joint model accounts for

residual dependency between the *K* time-to-event traits, not explained by the covariates shared by

the time-to-event sub-models. *Overall*, the proposed joint model for multiple longitudinal and

multiple time-to-event traits can improve inference by accounting for intermediate longitudinal

QT(s) and their dependencies, as well as dependencies among the time-to-event traits, and thereby

improve classification accuracy of direct and/or indirect SNP associations.

Implementation

Effect estimation and test statistic construction – To address computational obstacles involved in

the maximization of the joint likelihood and allow more flexible inference, we estimate the

parameters using a two-stage approach (see details in the Appendix). We work within the

framework originally defined by (Tsiatis et al. 1995; Wulfsohn and Tsiatis 1997; Dafni and Tsiatis

1998; Tsiatis and Davidian 2001) and in the spirit of subsequent authors (Ye et al. 2008; Yuen et

al. 2018; Arisido et al. 2019); (Tsiatis and Davidian 2001; Tsiatis and Davidian 2004) specify

conditions that guarantee the two-stage estimators are consistent and asymptotically normal.

Specifically, in Stage 1 we fit a multivariate mixed model (Equation 5) using the *mvlme*() function

from the R package JoineRML [(Hickey et al. 2018c), version 0.4.2] to estimate the parameters of

the longitudinal trajectories of the risk factors, and obtain fitted values of the smoothed trajectories.

In Stage 2, we fit a Cox PH frailty time-to-event model (Equations 6 or 7) adjusting for functions

of the smoothed trajectories as time-dependent covariates using the *coxph*() function from the R

package survival [(Therneau and Grambsch 2000; Therneau 2020), versions 3.2.7 and 3.2.13]. We

assume a Gamma distribution for the frailty term (u_i) and a separate non-parametric baseline

hazard function for each time-to-event trait using the strata argument in *coxph*().

To account for propagation of errors, due to uncertainty in Stage 1 estimates that is not accounted

for during Stage 2 parameter estimation (Wulfsohn and Tsiatis 1997), and to empirically estimate

the joint covariance matrix of SNP-QT trajectory ($\beta_{g,l}$) and SNP-TTE effects ($\gamma_{g,k}$), we apply a

nonparametric bootstrap. The bootstrap also provides reliable standard error estimates in the joint

time-to-event sub-model needed when using an unspecified baseline hazard (Hsieh et al. 2006;

Lawrence Gould et al. 2015; Furgal et al. 2019). For each bootstrap sample b ($1 \leq b \leq B$, B is the

total number of bootstrap repetitions), we generate a new dataset by randomly sampling N

individuals with replacement and refitting the joint model on each new dataset b. We compute the

empirical joint covariance matrix for all $\beta_{g,l}$, $\gamma_{g,k}$ and $\alpha_{l,k}$ parameter estimates using the B

bootstrap parameter vector estimates. Wald statistics for each $\beta_{g,l}$ are computed as $S_{\beta_g} =$

$\widehat{\beta_{g,l}}/se_{\beta_{g,l}}$ using the empirical bootstrap standard errors $se_{\beta_{g,l}}$ (to test H0: $\beta_{g,l} = 0$ *vs* H1: $\beta_{g,l} \neq$

0), and similarly for each $\gamma_{g,k}$ as $S_{\gamma_g} = \widehat{\gamma_{g,k}}/se_{\gamma_{g,k}}$ (to test H0: $\gamma_{g,k} = 0$ *vs* H1: $\gamma_{g,k} \neq 0$).

In contrast to the two-stage joint model, a conventional one-stage analysis to assess whether a SNP

has an association with the time-to-event trait, independent from the QT-TTE association, relies

on regression adjustment using observed longitudinal QT values as time-dependent covariates in

a Cox-PH model (Paterson et al. 2010; Deng and Pan 2017). This approach, based only on the

time-to-event model, does not provide information about SNP-QT association $(\beta_{g,l})$ and interprets

the SNP as having a direct association with the time-to-event if the test of SNP-TTE effect $(\gamma_{g,k})$ is

declared significant, given the observed QT. Inference for $\alpha_{l,k}$ under this approach can be biased

or inefficient when the QT is measured with random error or high within-subject variability

(Faucett and Thomas 1996; Wulfsohn and Tsiatis 1997; Xu and Zeger 2001; Song et al. 2002;

Brown and Ibrahim 2003), and inference for $\gamma_{g,k}$ may also be affected. Although estimates of the

SNP-QT effect $(\beta_{g,l})$ obtained from mixed model QT analysis, fitted separately, may be used to

distinguish between direct alone versus both direct and indirect SNP association, unlike the joint

model, this two-step conditional approach ignores measurement error in the observed QT values.

Procedure to classify direct and/or indirect SNP associations – In Table 1, we present a

practical procedure to classify a SNP as having direct and/or indirect association with a time-to-

event trait *k,* that accounts for the SNP association with a longitudinal risk factor *l*. This procedure

requires two significance thresholds, $P_{\beta_g}^*$ and $P_{\gamma_g}^*$ for hypothesis tests of each of $\beta_{g,l}$ and $\gamma_{g,k}$

respectively, to be specified prior to the analysis and adjusted for the number of SNPs tested.

Depending on the research question, we can choose different values for P_β^* and P_γ^*, or the same

value $(P^* = P_{\beta_g}^* = P_{\gamma_g}^*)$. The latter is applicable, for instance, to systematically classify direct

and/or indirect association for a set of *M* SNPs, and the former to assess which SNPs, among those

reported to be associated with the longitudinal risk factor, have a direct effect on a time-to-event

trait. To our knowledge, no comparable procedure to classify direct and/or indirect SNP

association, based on SNP effect estimates from joint models, has been proposed for studies with

longitudinal risk factors and time-to-event traits. A key feature of the proposed joint model

extension to multiple longitudinal and multiple time-to-event traits is inference for SNP effects on

each of the traits in a single integrated statistical model, while accounting for within-subject QT

variability and dependencies among the traits. The focus of the simulation study and DCCT data

application, which follow, is to evaluate the SNP classification procedure applied in extended joint

model analysis.

Simulation study

Design of the DCCT-data-based simulation study – To assess parameter estimation accuracy,

hypothesis testing for tests of each genetic effects under the proposed joint model, and evaluate

accuracy of the procedure we propose to classify SNPs as directly and/or indirectly associated with

a time-to-event trait, we generate $R=1000$ replicated datasets simulated under a *complex genetic*

architecture informed by the DCCT Genetics Study data (Fig. 3). The latter involves: $N=667$

subjects from the Conventional treatment group, $M=5$ simulated causal SNPs with direct effects

on $K=2$ simulated time-to-T1DC (with ~54% DR events and ~25% DN events on average) and/or

indirect effects via $L=3$ longitudinal QTs: two as measured in DCCT (HbA1c, SBP) and another

simulated QT (U) that is unmeasured and designed to induce shared dependency among the T1DC

traits. We assume effects of sex on SBP, and effects of T1D duration (at baseline) on both T1DC

traits, as estimated in the original DCCT data, and specify contemporaneous association structures

for the association of HbA1c and SBP on T1DC traits. We specify SNP effects and minor allele

frequencies (MAFs) of genetic associations, as well as other parameter values according to the

DCCT Genetics Study and the T1DC literature (Fig. 3). For SBP and DN, we inflate the typical

SNP effect sizes observed in the literature to achieve power sufficient to detect SNP associations

given the available DCCT sample size. Under the *global null genetic* scenario in which none of

the SNPs is associated with any traits, we also simulate M SNPs with the same MAFs as for the

causal SNPs, independently of the traits.

Algorithm for realistic data generation under a complex genetic architecture – To generate a data structure that combines observed and simulated traits, we formulate a genotype-phenotype multi-trait model including: *(i) L=3* linear mixed models linking each SNP with an indirect effect to a longitudinal risk factor, and *(ii) K=2* non-independent parametric time-to-event models depending on fitted longitudinal QT trajectories and SNPs with direct effects. For each DCCT individual *i* with observed longitudinal measures for HbA1c and SBP, and observed baseline covariates (T1D duration, sex), we simulate: genotypes at *M* causal SNPs with MAF vector *p*, longitudinal trait values U_i, and time-to-event traits ($(T_{i,k}, \delta_{i,k})$, *k*=1,2 for DR and DN), using the algorithm illustrated in Fig. 4 and detailed in File S2 (sections 1-5). All SNP genotypes are generated under Hardy-Weinberg and linkage equilibrium assumptions. SNPs with indirect effects through longitudinal QTs associated with DR and/or DN are generated from the observed (SNP1, SNP5) or simulated (SNP3) QTs, while SNPs with direct effects (SNP2, SNP4) are generated independently of the longitudinal QTs and are included in the hazard function used to generate each time-to-event trait (Fig. 4).

Scenario for DCCT-based complex genetic architecture – Overall, the complex genetic architecture represents multiple types of SNP-trait associations (Fig. 3): direct association with each T1DC trait (SNP2, SNP4), indirect association with both T1DC traits via measured (SNP1) and unmeasured (SNP3) longitudinal QTs; and direct and indirect association via a measured longitudinal QT (SNP5); all longitudinal risk factors exhibit within-subject random variability. Except for SNP3, all other SNP scenarios represent SNP association with a longitudinal QT risk factor (SNP1, SNP5) or a time-to-event trait (SNP2, SNP4, SNP5) testable in a single-trait GWAS.

SNP1, SNP3 and SNP5 have indirect effects on T1DC traits, such that their associations with the

T1DC traits are detectable in discovery analysis for each TTE trait, using Cox PH time-to-event

models fitted separately for each TTE trait and ignoring the longitudinal QT risk factors (File S2,

section 8). SNP1 corresponds roughly to rs10810632 and rs1358030 associations reported in the

motivating DCCT GWAS of HbA1c (Paterson et al. 2010), while SNP5 represents a strong signal

that would be detected in separate GWAS analysis of each longitudinal and time-to-event trait.

Analysis of the simulated data – To evaluate the statistical performance under the complex

genetic architecture outlined above, focusing on direct and/or indirect classification, we compare

extended joint model analysis of multiple longitudinal QT risk factors and multiple T1DC with

alternative analysis methods that do not fully exploit the data structure. These alternative

approaches include joint model analyses limited to two longitudinal QT and one time-to-event

trait, joint model analyses of one longitudinal QT and one time-to-event trait, and a conditional

time-to-event analysis of two time-to-event traits adjusted for observed values of two longitudinal

QTs. We assess the impact of model specification on the classification accuracy of direct and/or

indirect SNP associations by fitting mis-specified joint models that leave out important covariates

or traits. Altogether, the comparisons are designed to assess the merits of extended joint model

analysis over simpler available methods. In each replicated dataset, each of the five SNPs is

separately analysed for association with the longitudinal QTs and TTE traits, using four alternative

analytic approaches:

•   JM-cmp: a *completely* specified joint model analysis that includes observed (HbA1c, SBP)

and unobserved (U) longitudinal QT as well as baseline covariates (sex, T1D duration)

used in the data simulation. Due to the latent nature of unobserved U, JM-cmp cannot be

fitted in practice, but we include it as a benchmark for comparison against the data analysis

models JM-mis that are fitted without U.

• JM-mis: includes the same variables as in JM-cmp, but excludes U, the unobserved

longitudinal QT.

• JM-sep: joint models of *two* longitudinal traits and *one* time-to-event trait that do not

account for dependency between the time-to-event traits (where JM-sep ($l = 1,2$; $k=1$)

denotes the joint model for DR; and JM-sep($l = 1,2$; $k=2$) the joint model for DN), and

joint models of *one* longitudinal and *one* time-to-event trait that do not account for

dependence between the longitudinal traits, nor between the time-to-event traits (referred

to as JM-sep($l = 1$; $k=1$), JM-sep($l = 1$; $k=2$), and JM-sep($l = 2$; $k=2$)). Altogether, the JM-

sep models assess the merits of the extended joint model methods in comparison to JM-

mis and JM-cmp.

• CM-obs: a Cox PH frailty survival analysis of both time-to-event traits (DR, DN) that

includes the same variables as in JM-mis but adjusts for the *observed* longitudinal QT

values as time-dependent covariates; this model corresponds to the conditional analysis

approach mentioned above. Here, to classify SNPs as indirect association, we fit a linear

mixed model for both QTs to test the SNP effects on the QT(s) adjusted for the same

covariates as used for the joint models. Comparisons of estimation, hypothesis testing, and

classification results based on CM-obs to those based on JM-mis and JM-cmp allow us to

assess the impact of within-subject QT variation/measurement errors on hypothesis testing

and classification results for each SNP.

For each of these analyses, we compute empirical covariance matrices for the effect estimates

using 500 bootstrap iterations and construct large sample test statistics for each of the SNP effect

parameters. Under two-stage JM inference, in stage 1 we fit a bivariate ($l=1,2$) or univariate ($l=1$

or $l=2$) longitudinal QT model and test the $\beta_{g,l}$ parameters for indirect SNP association. Then in

stage 2, we fit the time-to-event models with the QT trajectories from stage 1 according to the TTE

model specification ($k=1,2$; $k=1$, or $k=2$), and test the $\gamma_{g,k}$ parameters for direct SNP association.

Because stage 1 QT analysis is shared among methods, differences in classification among analytic

methods largely arise through differences in the test results in stage 2 TTE analysis.

Under two-stage and conditional independence assumptions described in an Appendix, the SNP

association estimates of $\beta_{g,l}$ and $\gamma_{g,k}$ and corresponding test statistics are expected to be

uncorrelated under the *global null* scenario, but this may not necessarily hold under the *genetic*

alternative scenario when the analysis model is mis-specified or when the time-to-event estimation

uses observed longitudinal trait values. We therefore compute empirical correlations in each

replicate under both scenarios.

Given hypothesis test results for a pair of QT/TTE traits for each SNP, we apply the procedure

defined in Table 1 to classify the SNP-TTE association.

Evaluation criteria – We compare type I error and power of hypothesis tests of SNP-QT ($\beta_{g,l}$)

and SNP-TTE ($\gamma_{g,k}$) association among the alternative analytic approaches (JM-cmp, JM-mis, JM-

sep, CM-obs) under the *global null* and *causal* genetic scenarios for each of the 5 SNPs analysed

separately, at $P^* = 5\%$ and 1% critical values. We assess estimation accuracy using mean bias for

$\beta_{g,l}$ and $\gamma_{g,k}$ estimates, and confidence interval coverage across replicates, and similarly examine

the distribution and mean of their bootstrap standard errors and correlation for all the compared

models.

For each of the 5 SNPs, we evaluate accuracy of the procedure presented in Table 1 to classify

SNP association with each of the TTE traits as direct and/or indirect. Specifically, under the *global*

null and *causal genetic* scenarios, we compare the empirical classification frequencies to the

expected classification frequencies under the assumption of indirect and/or direct association built

into the generating model. The empirical frequencies are tabulated from the distribution of

simulation replicates in the four classification categories (direct, indirect, direct and indirect, not

direct and not indirect) as defined in Table 1, using specified classification thresholds such that

$P_\beta^* = P_\gamma^* = P^*$, with P^*=0.05. We calculate expected frequencies under the assumption that the Z

statistics, constructed from the estimates of $\beta_{g,l}$ and $\gamma_{g,k}$, and their bootstrap variances, follow a

bivariate normal distribution with correlation specified by the bootstrap estimates (see File S2,

section 9 for details), to allow for potential dependence between the SNP parameter tests. We judge

the classification procedure for a SNP association with each QT-TTE trait pair to have high

accuracy when the empirical frequencies are consistent with those expected, and we compare

accuracy among the different models. We also assess empirical classification frequencies for SNPs

with non-null effects across variation in stringency of significance thresholds up to P^*=10^{-5}.

Availability

DCCT data are available to authorized users at https://repository.niddk.nih.gov/studies/edic/

and https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000086.v3.p1

(IRB #07-0208-E). Example R codes for DCCT-data-based simulation and analysis of the

simulated data are provided on GitHub (https://github.com/brossardMyriam/Joint-model-for-

multiple-trait-genetics). Supplementary files are available online

(https://figshare.com/s/2b9f6b3da5e1f03e8086). File S1 includes the description of the DCCT

dataset as well as the list of the participants of the DCCT/EDIC Research Group; File S2

includes supplemental information for the DCCT-based simulation study; File S3 includes

supplemental information for the Analysis of the DCCT Genetics Study data; File S4 includes

the list of SNPs analyzed in DCCT; File S5 includes some notes on a multi-trait SNP association

test for SNP effects estimated under the proposed joint model framework. Computations were

run on the Niagara supercomputer (see

https://docs.computecanada.ca/wiki/Niagara#Niagara_hardware_specifications and

https://docs.scinet.utoronto.ca/index.php/Niagara_Quickstart for the hardware specifications and

characteristics). Computational resources and time used to fit the joint model of two quantitative

traits (HbA1c, SBP) and two time-to-event traits (DR, DN) in DCCT for one SNP are provided

as part of the discussion section.

RESULTS

Simulation Study

SNP association test validity and power – Under the *global null* scenario of no genetic

association with any of the traits, the type I error of each SNP test ($\beta_{g,l}$ and $\gamma_{g,k}$) is reasonably well

controlled (Table 2, left-hand side), and the *P*-values P_{β_g} and P_{γ_g} from the joint models show no

departure from the expected large sample distributions (χ^2 with 1 degree of freedom, see section

7 in File S2).

Under the alternative multi-SNP *causal genetic* scenario (Table 2, right-hand side), type I errors

for tests of each null $\beta_{g,l}$ tend to be close to the nominal level of 5% for most analysis models (with

exceptions for SNP2 and SNP5), while tests of the two SNPs with effects on intermediate

measured longitudinal QT risk factors (SNP1 ($\beta_{g,1}$) and SNP5 ($\beta_{g,2}$)) reach 100% power for all the

analysis models (Table 2, right-hand side). Tests of null $\gamma_{g,k}$ by JM-cmp, JM-mis and JM-

sep(l=1,2; k, with k=1 or 2) show overall good type I error control for all SNPs with direct and/or

indirect effects via measured longitudinal QTs (*i.e.* all SNPs but SNP3). However, for SNP1 with

indirect effects on both T1DC traits via HbA1c, tests of null $\gamma_{g,2}$ exhibit liberal type I errors in JM-

sep(l=2; k=2), which may be explained by bias in SNP1 effect on DN ($\widehat{\gamma_{g,2}}$, see File S2, section

6) towards the indirect SNP1 effect via HbA1c QT risk factor, which is ignored from JM-sep(l=2;

k=2). For SNP2 which has direct effect on DR ($\gamma_{g,1}$), tests of non-null $\gamma_{g,1}$ exhibit equivalent or

higher power under JM-cmp and JM-mis (closely followed by JM-sep(l=1,2; k)). However, the

power to detect the direct SNP4 effect on DN ($\gamma_{g,2}$) appears reduced in JM-sep(l=1; k=2); which

can be explained by the bias in $\widehat{\gamma_{g,2}}$ towards the null, due to ignoring SBP QT risk factor in JM-

sep(l=1; k=2). For SNP5 with direct and indirect effects on DN via SBP, $\gamma_{g,2}$ appears detected by

a larger number of replicates under JM-sep(l=1; k=2) and CM-obs (Table 2, right-hand side);

which may be explained by bias in SNP5 effect ($\widehat{\gamma_{g,2}}$, see File S2, section 6) towards the overall

SNP5 effect (combining direct and indirect SNP5 effects via SBP), given that SBP is ignored from

JM-sep(l=1; k=2) and random SBP variation in CM-obs. Finally, for SNP3 that has indirect effects

on both T1DC traits via the *unmeasured* longitudinal risk factor U, only JM-cmp accounts for

indirect SNP3 pathways via U. This translates into elevated type I errors for tests of each null $\gamma_{g,k}$

likely explained by the biased SNP3 effects on both T1DC traits ($\widehat{\gamma_{g,k}}$, see File S2, section 6) in

JM-mis, all JM-sep, and CM-obs, towards the indirect SNP3 effect via U. Overall, the relative

ranking of empirical powers among the analysis models persists for tests of each $\gamma_{g,k}$ across $P*$

varying up to 10^{-5} (File S2, section 8), with steeper power reduction for detection of SNP4 effect

on DN ($\gamma_{g,2}$) in JM-sep($l=1$; $k=2$), and markedly misleading detection of SNP5 effect on DN ($\gamma_{g,2}$)

in JM-sep($l=1$; $k=2$) and CM-obs.

As noted above, the improvement of the type I errors control and powers in tests of each $\gamma_{g,k}$ under

the alternative simulation scenario by JM-cmp (closely followed by JM-mis and JM-sep($l=1,2$;

$k=1$ or 2)) compared to JM-sep($l=1$ or 2; $k=1$ or 2) for one longitudinal and one time-to-event trait

and CM-obs can be explained by more efficient estimation accuracy in $\widehat{\gamma_{g,k}}$, but also in the QT

effect estimates on the TTE ($\widehat{\alpha_{l,k}}$) as illustrated by: bias reduction, coverage probabilities closer to

the nominal level (95%), and empirical 95% confidence intervals of the parameter estimates

narrower around the true parameter (File S2, section 6). Moreover, we find little evidence for

correlation between $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$. The average bootstrap correlation $\widehat{\rho_{l,k}}$ across replicates is low

for each QT/TTE trait pair (l; k) under the *alternative genetic* (Tables 3-7) and *global null* scenarios

(File S2, section 9) for all joint model analyses ($\left|\widehat{\rho_{l,k}}\right| < 0.05$). However, we see larger $\left|\widehat{\rho_{l,k}}\right|$

values in CM-obs, particularly for the SBP/DN trait pair; this may be explained by larger random

variation in SBP which is ignored by CM-obs.

Classification of direct and/or indirect SNP associations with time-to-event traits –

Under the *global null* scenario, the empirical classification frequencies for direct and/or indirect

SNP association with each T1DC trait at significance level $P^* = 0.05$ agree with the expected

classification frequencies for all the categories of SNP associations and for all the models (File S2,

section 9); this observation confirms the accuracy of the proposed hypothesis procedure under the

global null genetic scenario. We also find the expected classification frequencies to be insensitive

to larger bootstrap correlation values ($\left|\widehat{\rho_{l,k}}\right| < 0.4$, see File S2, section 9). Overall, empirical and

expected classification frequencies are close to the nominal rate of 5% for the categories of direct

or indirect association, but conservative for the category of direct and indirect association (see File

S2, section 10); which requires rejection of single-parameter hypothesis for the two tests of SNP

effects $\beta_{g,l}$ and $\gamma_{g,k}$ (Table1).

Under the *alternative* simulation scenario, when SNPs have direct and/or indirect effects via

measured longitudinal QTs, we find that the proposed multivariate joint models, JM-cmp, JM-mis

(and JM-sep(l=1,2; k with k=1 or 2)) lead to improved classification accuracy (empirical

classification frequencies closer to the expected ones for each of the four categories of association)

at specified significance level $P^* = 0.05$, and correctly classify the simulated SNP associations for

each trait pair in more than 88% of replicates for SNP1, SNP2 and SNP4 (Tables 3 to 5), and in

more than 61% of replicates for SNP5 (Table 6). In contrast, JM-sep(l=1 or 2; k=1 or 2) and CM-

obs models exhibit larger differences between empirical and expected classification frequencies,

which suggests lower ability of these models to correctly distinguish between direct and/or indirect

association; which can lead to misleading inference. This is especially the case for the SNPs with

bias in $\widehat{\gamma_{g,k}}$ and low type I error control or power for test of $\widehat{\gamma_{g,k}}$ in JM-sep(l=1 or 2; k=1 or 2) and

CM-obs models, as illustrated for:

• SNP1 that has indirect association with both T1DC traits via HbA1c; it exhibits lower-

than-expected empirical classification frequencies for the correct association category

with HbA1c/DR (indirect association) and with SBP/DN (not direct and not indirect

association), see Table 3;

• SNP4 that has a direct association with DN, with lower than expected empirical

classification frequency for the correct direct association category with HbA1c/DN in JM-

sep(l=1; k=2) as shown in Table 5;

•   SNP5 with direct and indirect effects on DN via SBP, which exhibit larger than expected

622   empirical classification frequencies for the correct association category with HbA1c/DN

623   (direct association), and with SBP/DN (direct and indirect association), see Table 6.

On the other hand, for SNP3 which has indirect effects on both T1DC traits via the unmeasured

longitudinal QT risk factor (U); except JM-cmp which exhibits accurate (and high) classification

frequencies, all the other compared models (which ignore U), exhibit poor classification accuracy

(Table 7) and tend to mistakenly classify SNP3 as a direct association with each T1DC trait in

~30-86% of the replicates.

As stringency of P^* increases up to 10^{-5} for the same effect sizes, empirical classification

frequencies decrease in the correct association category, while mis-classification frequencies

increase in the other categories; for example SNP5 tends to be mistakenly classified as an indirect

association with SBP/DN with JM-cmp (File S2, section 11).

In summary, our simulations show that by using smoothed trajectories and accounting for all QT

associations, the extended joint model improves parameter estimation efficiency and classification

accuracy of SNPs directly associated with each time-to-event trait or indirectly associated via a

measured longitudinal QT in comparison to classification using JM-sep models for analysis of

each time-to-event trait with one or multiple longitudinal traits or CM-obs. Reduced classification

accuracy translate to increased risk of misclassifying a SNP as direct and/or indirect association.

In addition, when a SNP has both direct and indirect effects on a time-to-event trait, the proposed

classification procedure can be conservative because it requires the joint significance of the two

SNP effects, $\beta_{g,l}$ and $\gamma_{g,k}$, where the power of each test depends on effect size, MAF and trait

distribution. As a result, a SNP with both direct and indirect associations can be misclassified as

either a direct or an indirect association, as we will also illustrate in the application results in

DCCT. Finally, when a SNP has an indirect effect on both T1DC traits via an unmeasured QT, the

testing procedure based on JM-mis, that captures some of the unmodeled dependency between

time-to-event traits through the frailty term, does not prevent misclassification as a direct

association, which could be due to the limitation of using a time-invariant frailty term. In addition,

this observation also demonstrates the importance of the proposed joint model extension, which

allows analysis on all the intermediate QT(s), as opposed to JM-sep, to avoid misclassification of

direct and/or indirect SNP associations.

Application in the DCCT Genetics Study data

We demonstrate feasibility of the proposed two-stage extended joint model method by analysis in

the DCCT Genetics Study data. The application is based on DCCT individuals from the

Conventional treatment group genotyped on HumanCoreExome Bead Array (Illumina, San Diego,

CA, USA) with ungenotyped autosomal SNPs imputed using 1000 Genomes data phase 3 (The

1000 Genomes Project Consortium 2015), as detailed in File S1. We use time to mild retinopathy

and time to persistent microalbuminuria, for DR and DN outcomes respectively, as previously

defined in the motivating GWAS of HbA1c (Paterson et al. 2010); see File S3, section 1 for details.

Out of 667 conventionally-treated DCCT individuals with genetic data, we analyze N=516

subjects, excluding those with mild to moderate non-proliferative retinopathy or DN at DCCT

baseline. By the time of the DCCT close-out visit, 297 (57.6%) had a DR event, and 61 (11.8%)

had a DN event, including 47 subjects (9.1%) that experienced both events. After SNP filtering

and pruning on linkage disequilibrium (File S3, section 2), we analyze 307 SNPs reported as

associated with HbA1c, SBP, or multiple definitions of DR and/or DN (Paterson et al. 2010; Grassi

et al. 2011; Sandholm et al. 2012; Hosseini et al. 2015; Wheeler et al. 2017; Evangelou et al. 2018;

Pollack et al. 2019), see File S4 for the full list of SNPs.

Joint model fitting – We fit the joint model for each SNP one at a time, including baseline

covariates (age at diagnosis, T1D duration, cohort, sex, and year of DCCT study entry),

longitudinal HbA1c and SBP, and T1DCs DR and DN (File S3, section 3). Given prior evidence

for long term HbA1c effects on T1DC, we present results under the time-weighted cumulative for

HbA1c association with time-to-T1DC traits, which exhibits stronger prior association with T1DC

in the DCCT individuals analyzed here, but we obtained similar classification results under the

two alternative specifications considered for HbA1c association (i.e. contemporaneous value and

updated mean, see File S3, section 4). We apply diagnostic tools in the joint model analysis,

including residual analysis in the longitudinal and time-to-event sub-models, finding little

evidence for model misspecification (File S3, section 5). In the Cox PH frailty time-to-event sub-

model, PH assumptions are well-satisfied when the baseline hazard is stratified on the cohort

variable; overall conclusions are equivalent when cohort is included as a covariate. As shown in

File S3 (section 5), the martingale residuals of the Cox PH frailty model are consistent with the

assumption of a linear relationship between the QTs and each time-to-T1DC outcome.

In Fig. 5 (Panel A), we show that rs1358030 and rs10810632, which were discovered in a previous

GWAS of HbA1c in DCCT (Paterson et al. 2010), are classified as indirect associations with both

T1DC traits via their association with the HbA1c shared risk factor ($P_{\beta_g} \leq P^*$ and $P_{\gamma_g} > P^*$,

$P^* = 1.7 \times 10^{-4}$ after Bonferroni correction for the 289.02 effective SNPs tested (Li and Ji 2005)).

Although the other candidate SNPs were selected from larger meta-analysis in T1D and/or

independent studies in general populations (Paterson et al. 2010; Grassi et al. 2011; Sandholm et

al. 2012; Hosseini et al. 2015; Wheeler et al. 2017; Evangelou et al. 2018; Pollack et al. 2019), the

SNP-trait association tests did not reach Bonferroni-corrected significance thresholds in our

analysis (File S3, section 4), potentially due to effect heterogeneity and low power to detect these

variants or by some inherent heterogeneity factors in the study designs and/or phenotypic

definitions. Thus, classification for these candidate SNPs is uninformative.

Sample size and power considerations –The DCCT-based simulation study shows that multiple-

trait joint model analysis can achieve high classification rates for direct and/or indirect SNP

associations under SNP effect sizes in the specified range (SNP effects: on the QTs 0.7-7, on T1DC

0.4-0.8; and MAFs 10-40%) and classification rates under the global null hypothesis (null SNP

effects on all traits) controlled to the nominal levels for direct or indirect SNP association but

conservative for direct and indirect association. Compared to the simulation, the number of DN

events is lower in the DCCT data application. We thus expect lower power to detect direct SNP

association with DN; this implies reduced accuracy to classify a SNP as having either a direct, or

a direct and indirect association.

In light of the simulation results, we acknowledge that a larger sample size would be required to

maintain performance in DCCT for genetic associations with lower MAFs/effect sizes than the

ones specified. In particular, lower effect sizes and MAFs can lead to larger variances of estimated

effects and larger 95% confidence intervals, as observed for the direct effects of rs10810632

(MAF=7%) compared to rs1358030 (MAF=36%) for both time-to-T1DC traits (Fig. 5, Panels B

and C). SNP effects with larger variances have lower power to detect association. Although we

expect the effect sizes estimated by the joint model to be relatively insensitive to the study sample

size, reduction in variances by increasing study sample size would be expected to improve

classification accuracy for these two SNPs (particularly for rs10810632 that has a lower MAF).

To assess how genetic association and classification results for rs10810632 and rs1358030 may be

affected by increasing sample size, we applied parametric resampling (see File S3, section 6 for

details) to draw datasets with sample size up to five times the DCCT sample of $N=516$, and we

then extrapolated the classification beyond $N=2580$. This analysis demonstrates decreasing

variances of the SNP effects for both SNPs as sample size increases and narrowing of the 95% and

99% confidence intervals (File S3, section 6); panel A in Fig. 6 illustrates the corresponding shift

in classification of rs10810632 association with DR as indirect via HbA1c towards classification

as both indirect and direct. On the other hand, given that both SNPs were previously discovered in

a GWAS of HbA1c in DCCT, SNP effect estimates for HbA1c association ($\widehat{\beta_{g,1}}$) may be

overestimated due to Winner's curse bias (Kraft 2008; Sun et al. 2011), which would impact the

classification results. We therefore repeated the sample size analyses specifying an adjusted SNP

effect size for the HbA1c association equal to 50% of its effect estimate in our DCCT analysis. In

this scenario the test of SNP association with HbA1c falls just below the $P*$ threshold in the

resample size $N=516$, although power improves in larger sample sizes (Fig. 6). Here again

classification tends to shift from indirect towards both direct and indirect SNP associations with

both T1DC traits (see File S3, section 6 for complete results for both SNPs); however, a much

larger sample size is needed to cross the $P*$ threshold for test of direct association.

In the DCCT application, we take advantage of the largest available clinical study of T1D

complications with long-term follow-up and high-density longitudinal QT measurements. This

highlights the dearth of longitudinal studies with both a large number of individuals and long-term

730 clinical follow-up, as well as the related challenges in joint model analysis. In prospective study

731 designs with both longitudinal and time-to-event traits, an inherent imbalance can exist among

732 traits in detection of SNP associations, in that power for QT(s) depends on the number of

733 measurements while power for time-to-event traits depends on the number of events and duration

734 of follow-up. Although there is currently a trade-off between epidemiological studies with large

735 sample sizes but low density of longitudinal measurements, and clinical studies with more modest

736 sample sizes but high measurement densities, we anticipate informative application of joint model

737 analysis in large biobanks, for example (Scholtens et al. 2015; Bycroft et al. 2018; Dummer et al.

738 2018), now assembling longitudinal measures jointly with binary outcomes and genetic data.

739 **DISCUSSION**

740 We present new, more informative methods for statistical genetic analysis under a joint model

741 specification of multiple longitudinal risk factors and multiple time-to-event traits, designed to

742 characterize the complex genetic architecture of related traits in longitudinal studies of disease

743 progression. The proposed extended model is formulated to deal with dependencies within and

744 between traits and can account for trait-specific and shared covariates, within-subject random

745 variability in the longitudinal traits, as well as effects of unobserved baseline confounding factors

746 between the time-to-event traits through a subject-specific frailty term. We also introduce a

747 realistic data-based simulation algorithm to assess joint model performance that can also be used

748 to estimate achievable power in clinical studies such as DCCT characterized by extensive

749 longitudinal follow-up but limited sample size.

Evaluation by realistic simulation study of complex T1DC genetic architecture shows that

accounting for trait dependencies and measurement errors in longitudinal QT risk factors using the

proposed joint model extension improves classification accuracy of SNP as direct and/or indirect

association compared to *(i)* separate joint model analysis of each time-to-event trait with one or

multiple longitudinal traits, and *(ii)* Cox-PH frailty model analysis adjusted for multiple observed

longitudinal trait values. This improvement in classification accuracy under the joint models of

multiple longitudinal and multiple TTE traits results from improved Type I error control for single-

parameter tests of each of the two SNP effects ($\beta_{g,l}$ or $\gamma_{g,k}$), and improved power to detect SNP

association, that can be explained by reduced estimation bias in parameters. However, we also

observe that estimation bias and misclassification can be severe in the presence of SNP association

with a longitudinal risk factor that is unmeasured or absent from the joint model, and mis-

classification may be non-negligible when the study has limited power to detect either of the two

SNP effects ($\beta_{g,l}$ or $\gamma_{g,k}$), as in the DCCT study. We apply parametric resampling to evaluate how

study sample size or Winner's curse bias affects classification accuracy and anticipate that this

approach may also help inform replication study design with sufficient power. Nevertheless, we

conclude that application of joint model analysis in longitudinal studies of disease progression,

such as in the DCCT Genetics Study, improves classification of direct and/or indirect SNP

association and helps to elucidate the genetic architecture of complex traits.

Although the primary aim in this report is to develop statistical methods to distinguish among

direct and/or indirect SNP associations with each time-to-event trait, the multi-trait extension of

the joint model lends itself to development of multi-trait SNP association testing for SNP

discovery. In File S5, we present a joint-parameter test for global SNP association with all the

longitudinal and time-to-event traits, based on a generalized Wald statistic. In application to the

simulated DCCT-based complex genetic architecture, we observe good type I error control under

the global genetic null scenario, improved power for SNP discovery when a SNP has multiple trait

effects, and power maintenance in other SNP association scenarios.

Although the extended joint model can be applied to studies where longitudinal QT measurements

are missing at some of the visits, choice of the joint model estimation method depends on the

missing data mechanism. In the presence of informative missing data mechanisms, we recommend

sensitivity analysis using existing implementations of joint likelihood estimation that assume the

time-to-dropout mechanism depends on missing longitudinal QT values through the posterior

distribution of the random effects; this corresponds to an informative missing data mechanism

(Rizopoulos 2012). To our knowledge these implementations exist only for simple joint model

formulations with either one longitudinal and one time-to-event trait (Rizopoulos 2010) or with

multiple longitudinal traits and one time-to-event outcome (Rizopoulos 2016; Hickey et al. 2018c).

Alternatively multiple imputation methods have been implemented for two-stage estimation

(Rubin 1987; Moreno-Betancur et al. 2018); these impute missing values for multiple longitudinal

continuous traits using the conditional distribution of each QT trait given one time-to-event trait

and other QTs. More generally for missing data, further development of methods to maximize the

extended joint likelihood, for example using Bayesian methods, would alleviate numerical

challenges with increasing model complexity in multivariate extensions of joint models (Lawrence

Gould et al. 2015); but this would require the design of an efficient sampling algorithm to study

the posterior distribution.

We acknowledge several features of the joint model approach that warrant examination in further

work. *Firstly*, to reduce computational complexity and improve model flexibility, we use two-

stage parameter estimation. In some circumstances, this approach can produce biased estimates in

the longitudinal and/or time-to-event sub-models as well as underestimation of their standard

errors (Tsiatis et al. 1995; Wulfsohn and Tsiatis 1997; Dafni and Tsiatis 1998; Ye et al. 2008;

Albert and Shih 2010; Sweeting and Thompson 2011; Ye and Wu 2017; Huong et al. 2018; Mauff

et al. 2020). Biased estimates can result from informatively missing data in the presence of non-

random censoring of the longitudinal trait values due to the occurrence of an event or from

informative dropout (Ye et al. 2008; Albert and Shih 2010; Mauff et al. 2020). The simulation

results show minimal biases in the absence of informative censoring, even when an associated

longitudinal QT variable is omitted from the joint model. In the DCCT application, characterized

by administrative censoring and a high completion rate, these biases are of less concern because

longitudinal trait values continued to be recorded on a pre-specified visit schedule regardless of

the occurrence of any T1DC events; we estimated the trajectories using all the available

measurements. Furthermore, we obtain robust non-parametric bootstrap estimates of the

covariance matrix for the SNP effects, and simulation results under the null do not show deviation

from expected distributions. *Secondly*, because the joint model integrates longitudinal and time-

to-event sub-models, model misspecification can occur in multiple ways and lead to invalid

inference (Arisido et al. 2019). We recommend a careful assessment of model assumptions and

data-based simulation studies to evaluate the robustness of classification of direct and/or indirect

associations to two-stage assumptions. In the DCCT application, we provide an illustration of

diagnostic analyses which could serve as guidance in other applications. *Thirdly*, patient visits

were scheduled with high frequency in DCCT, so we ignored the modest degree of interval

censoring in the current implementation of the joint model; when there are longer gaps between

visits, extended methods are needed to account for interval censoring in the time-to-event sub-

model with additional simulation studies to assess impact on joint model estimates.

Computationally, joint model fitting can be very demanding, particularly for genetic association

studies that test millions of variants. In the DCCT application, it took ~1 minute to fit the joint

model for each SNP and ~ 18 more minutes to estimate the covariance matrix with 500 bootstraps

run in parallel on 4 nodes (each node with 40 CPU and 202 GB RAM). While analysis at the

genome-wide level, involving for example ~9 million imputed autosomal SNPs in DCCT Study

(Roshandel et al. 2018), is computationally unrealistic at present, a screening approach without

bootstrap to select informative SNPs, followed by bootstrap refinement would reduce the

computational burden to feasible levels. Recently, computationally efficient algorithms have been

developed to improve feasibility of linear mixed model (Sikorska et al. 2018) and Cox PH model

(Rizvi et al. 2019; Bi et al. 2020) analyses for genome-wide genetic association studies, but to

date, they remain to be implemented for multivariate outcomes. *Lastly*, (Liu et al. 2018) discuss

various formulations and interpretations of joint models in the context of mediation analysis, with

shared-random-effects accounting for potential unmeasured baseline confounding factors between

one longitudinal and one time-to-event traits. Using applications in datasets from two clinical

trials, they illustrate interpretation of sensitivity analysis to unmeasured baseline confounders.

Adaptation of the joint model we propose for multiple longitudinal and multiple time-to-event

traits for mediation analysis requires extension of the mediation assumptions (Sobel 1982;

Mackinnon et al. 1995) to the case of multiple mediators and multiple time-to-event traits. Specific

evaluations of the proposed model under these assumptions are also warranted.

We expect application of joint model methods in large biobank datasets to be informative in

characterization of the genetic architecture of complex traits. Some extensions of joint models

have been proposed to account for additional challenges raised by large biobanks, for example

informative visiting processes (Gasparini et al. 2020). By providing more efficient SNP effect

estimates and increased precision in polygenic risk score development, results of such analysis

have potential to contribute to the translation of human genetic findings into personalized medicine

(Young et al. 2019), as well as to causal inference using mediation and mendelian randomization

studies. Finally, the joint model framework has potential to enable dynamic prediction beneficial

for dynamic risk assessment (Papageorgiou et al. 2019; Bull et al. 2020) and optimization of

intervention strategies (Sweeting and Thompson 2011; Yuen et al. 2018).

Acknowledgements

This study uses data provided by the Diabetes Control and Complications Trial / Epidemiology of

Diabetes Interventions and Complications (DCCT/EDIC) Research Group which is sponsored

through research contracts from the National Institute of Diabetes, Endocrinology and Metabolic

Diseases of the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) and the

National Institutes of Health (NIH). The authors are grateful to the subjects in the DCCT/EDIC

cohort for their long-term participation. A complete list of the individuals and institutions

participating in the DCCT/EDIC Research Group can be found in File S1. This project was

supported by: CIHR Operating/Project Grants (#MOP-84287, #PJT-159509, #PJT-159463),

CANSSI Collaborative Research Team in "Statistical methods for the analysis of genetic data with

survival outcomes", CANSSI postdoctoral fellowship (MB), CIHR STAGE fellowships (MB and

OEG, #GET-101831). Computations were performed on the Niagara supercomputer at the SciNet

HPC Consortium. SciNet is funded by the Canada Foundation for Innovation under the auspices

Abbreviations

DAG: directed acyclic graph;

DCCT: Diabetes control and complications trial;

DR: diabetic retinopathy;

DN: diabetic nephropathy;

GWAS: genome-wide association study;

HbA1c: Hemoglobin A1c;

LD: linkage disequilibrium;

MAF: minor allele frequency;

PH: proportional hazards;

QT(s): quantitative trait(s);

SBP: systolic blood pressure;

SNP: single nucleotide polymorphism;

T1DC: type 1 diabetes complications;

TTE: time-to-event.

Literature cited

Albert PS, Shih JH. 2010. On estimating the relationship between longitudinal measurements

and time-to-event data using a simple two-stage procedure. Biometrics. 66(3):983–991.

doi:10.1111/j.1541-0420.2009.01324_1.x. https://about.jstor.org/terms.

Arisido MW, Antolini L, Bernasconi DP, Valsecchi MG, Rebora P. 2019. Joint model robustness

compared with the time-varying covariate Cox model to evaluate the association between a

longitudinal marker and a time-to-event endpoint. BMC Med Res Methodol. 19(1):222.

doi:10.1186/s12874-019-0873-y. http://www.ncbi.nlm.nih.gov/pubmed/31795933.

Asar Ö, Ritchie J, Kalra PA, Diggle PJ. 2015. Joint modelling of repeated measurement and

time-to-event data: An introductory tutorial. Int J Epidemiol. 44(1):334–344.

doi:10.1093/ije/dyu262.

Bi W, Fritsche LG, Mukherjee B, Kim S, Lee S. 2020. A fast and accurate method for genome-

wide time-to-event data analysis and its application to UK Biobank. Am J Hum Genet.

107(2):222–233. doi:10.1016/j.ajhg.2020.06.003. https://doi.org/10.1016/j.ajhg.2020.06.003.

Brent RP. 2013. Algorithms for minimization without derivatives. Courier Co.

Brown ER, Ibrahim JG. 2003. A Bayesian semiparametric joint hierarchical model for

longitudinal and survival data. Biometrics. 59(2):221–8. doi:10.1111/1541-0420.00028.

http://www.ncbi.nlm.nih.gov/pubmed/12926706.

Bull L, Lunt M, Martin G, Hyrich K, Sergeant J. 2020. Harnessing repeated measurements of

predictor variables for clinical risk prediction: a review of existing methods. Diagnostic Progn

Res. 4(1):1–16. doi:10.1186/s41512-020-00078-z.

Bycott P, Taylor J. 1998. A comparison of smoothing techniques for CD4 data measured with

error in a time-dependent Cox proportional hazards model. Stat Med. 17(18):2061–77.

doi:10.1002/(sici)1097-0258(19980930)17:18<2061::aid-sim896>3.0.co;2-o.

http://www.ncbi.nlm.nih.gov/pubmed/9789914.

Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,

Delaneau O, O'Connell J, et al. 2018. The UK Biobank resource with deep phenotyping and

genomic data. Nature. 562(7726):203–209. doi:10.1038/s41586-018-0579-z. [accessed 2019 Aug

6]. http://www.nature.com/articles/s41586-018-0579-z.

Chen LM, Ibrahim JG, Chu H. 2011. Sample size and power determination in joint modeling of

longitudinal and survival data. Stat Med. 30(18):2295–2309. doi:10.1002/sim.4263.

Crowther MJ, Lambert PC. 2013. Simulating biologically plausible complex survival data. Stat

Med. 32(23):4118–4134. doi:10.1002/sim.5823.

Dafni UG, Tsiatis AA. 1998. Evaluating surrogate markers of clinical outcome when measured

with error. Biometrics. 54(4):1445–1462. doi:10.2307/2533670. [accessed 2019 Jul 12].

https://www.jstor.org/stable/2533670?origin=crossref.

Deng Y, Pan W. 2017. Conditional analysis of multiple quantitative traits based on marginal

GWAS summary statistics. Genet Epidemiol. 41(5):427–436. doi:10.1002/gepi.22046.

https://onlinelibrary.wiley.com/doi/10.1002/gepi.22046.

Dummer TJB, Awadalla P, Boileau C, Craig C, Fortier I, Goel V, Hicks JMT, Jacquemont S,

Knoppers BM, Le N, et al. 2018. The Canadian Partnership for Tomorrow Project: A pan-

Canadian platform for research on chronic disease prevention. Cmaj. 190(23):E710–E717.

doi:10.1503/cmaj.170292.

Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou

N, Cabrera CP, Karaman I, et al. 2018. Genetic analysis of over 1 million people identifies 535

new loci associated with blood pressure traits. Nat Genet. 50(10):1412–1425.

doi:10.1038/s41588-018-0205-x. http://www.ncbi.nlm.nih.gov/pubmed/30224653.

Faucett CL, Thomas DC. 1996. Simultaneously modelling censored survival data and repeatedly

measured covariates: a Gibbs sampling approach. Stat Med. 15(15):1663–85.

doi:10.1002/(SICI)1097-0258(19960815)15:15<1663::AID-SIM294>3.0.CO;2-1.

http://www.ncbi.nlm.nih.gov/pubmed/8858789.

Furgal AKC, Sen A, Taylor JMG. 2019. Review and comparison of computational approaches

for joint longitudinal and time-to-event models. Int Stat Rev. 87(2):insr.12322.

doi:10.1111/insr.12322. [accessed 2019 Jul 11].

https://onlinelibrary.wiley.com/doi/abs/10.1111/insr.12322.

Gasparini A, Abrams KR, Barrett JK, Major RW, Sweeting MJ, Brunskill NJ, Crowther MJ.

2020. Mixed-effects models for health care longitudinal data with an informative visiting

process: A Monte Carlo simulation study. Stat Neerl. 74(1):5–23. doi:10.1111/stan.12188.

Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. 2011. Genome-wide

meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 20(12):2472–2481.

doi:10.1093/hmg/ddr121.

Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2016. Joint modelling of time-to-

event and multivariate longitudinal outcomes: recent developments and issues. BMC Med Res

Methodol. 16(1):117. doi:10.1186/s12874-016-0212-5. http://dx.doi.org/10.1186/s12874-016-

0212-5.

Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2018a. Joint models of

longitudinal and time-to-event data with more than one event time outcome: A review. Int J

Biostat. 14(1). doi:10.1515/ijb-2017-0047.

https://www.degruyter.com/document/doi/10.1515/ijb-2017-0047/html.

Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2018b. A comparison of joint

models for longitudinal and competing risks data, with application to an epilepsy drug

randomized controlled trial. J R Stat Soc Ser A Stat Soc. 181(4):1105–1123.

doi:10.1111/rssa.12348. [accessed 2023 Mar 24].

https://academic.oup.com/jrsssa/article/181/4/1105/7072031.

Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2018c. joineRML: a joint model

and software package for time-to-event and multivariate longitudinal outcomes. BMC Med Res

Methodol. 18(1):50. doi:10.1186/s12874-018-0502-1. [accessed 2019 Apr 23].

https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-018-0502-1.

Hogan JW, Laird NM. 1998. Increasing efficiency from censored survival data by using random

effects to model longitudinal covariates. Stat Methods Med Res. 7(1):28–48.

doi:10.1177/096228029800700104.

http://journals.sagepub.com/doi/10.1177/096228029800700104.

Hosseini SM, Boright AP, Sun L, Canty AJ, Bull SB, Klein BEK, Klein R, Paterson AD. 2015.

The association of previously reported polymorphisms for microvascular complications in a

meta-analysis of diabetic retinopathy. Hum Genet. 134(2):247–257. doi:10.1007/s00439-014-

1517-2.

Hougaard P. 1995. Frailty models for survival data. Lifetime Data Anal. 1(3):255–273.

doi:10.1007/BF00985760. http://link.springer.com/10.1007/BF00985760.

Hsieh F, Tseng YK, Wang JL. 2006. Joint modeling of survival and longitudinal data:

Likelihood approach revisited. Biometrics. 62(4):1037–1043. doi:10.1111/j.1541-

0420.2006.00570.x.

Huong PTT, Nur D, Pham H, Branford A. 2018. A modified two-stage approach for joint

modelling of longitudinal and time-to-event data. J Stat Comput Simul. 88(17):3379–3398.

doi:10.1080/00949655.2018.1518449.

Ibrahim JG, Chen M-H, Sinha D. 2001. Joint Models for Longitudinal and Survival Data. In:

Canadian Medical Association journal. Vol. 130. p. 262–289.

http://link.springer.com/10.1007/978-1-4757-3447-8_7.

Ibrahim JG, Chu H, Chen LM. 2010. Basic concepts and methods for joint models of

longitudinal and survival data. J Clin Oncol. 28(16):2796–2801. doi:10.1200/JCO.2009.25.0654.

Jensen SM, Ritz C. 2018. A comparison of approaches for simultaneous inference of fixed

effects for multiple outcomes using linear mixed models. Stat Med. 37(16):2474–2486.

doi:10.1002/sim.7666. https://onlinelibrary.wiley.com/doi/10.1002/sim.7666.

Kraft P. 2008. Curses--winner's and otherwise--in genetic epidemiology. Epidemiology.

19(5):649–51; discussion 657-8. doi:10.1097/EDE.0b013e318181b865.

http://www.ncbi.nlm.nih.gov/pubmed/18703928.

Laird NM, Ware JH. 1982. Random-effects models for longitudinal data. Biometrics. 38(4):963–

74. http://www.ncbi.nlm.nih.gov/pubmed/7168798.

Lawrence Gould A, Boye ME, Crowther MJ, Ibrahim JG, Quartey G, Micallef S, Bois FY. 2015.

Joint modeling of survival and longitudinal non-survival data: Current methods and issues.

Report of the DIA Bayesian joint modeling working group. Stat Med. 34(14):2181–2195.

doi:10.1002/sim.6141.

Li J, Ji L. 2005. Adjusting multiple testing in multilocus analyses using the eigenvalues of a

correlation matrix. Heredity (Edinb). 95(3):221–227. doi:10.1038/sj.hdy.6800717.

http://www.ncbi.nlm.nih.gov/pubmed/16077740.

Lind M, Odén A, Fahlén M, Eliasson B. 1995. The Relationship of Glycemic Exposure (HbA1c)

to the Risk of Development and Progression of Retinopathy in the Diabetes Control and

Complications Trial. Diabetes. 44(8):968–983. doi:10.2337/diab.44.8.968.

https://diabetesjournals.org/diabetes/article/44/8/968/8802/The-Relationship-of-Glycemic-

Exposure-HbA1c-to-the.

Lind M, Odén A, Fahlén M, Eliasson B. 2010. The shape of the metabolic memory of HbA1c:

Re-analysing the DCCT with respect to time-dependent effects. Diabetologia. 53(6):1093–1098.

doi:10.1007/s00125-010-1706-z.

Liu L, Zheng C, Kang J. 2018. Exploring causality mechanism in the joint analysis of

longitudinal and survival data. Stat Med. 37(26):3733–3744. doi:10.1002/sim.7838.

Mackinnon DP, Warsi G, Dwyer JH. 1995. A simulation study of mediated effect measures.

Multivariate Behav Res. 30(1):41. doi:10.1207/s15327906mbr3001_3.

http://www.ncbi.nlm.nih.gov/pubmed/20157641.

Mauff K, Steyerberg E, Kardys I, Boersma E, Rizopoulos D. 2020. Joint models with multiple

longitudinal outcomes and a time-to-event outcome: a corrected two-stage approach. Stat

Comput. 30(4):999–1014. doi:10.1007/s11222-020-09927-9.

http://link.springer.com/10.1007/s11222-020-09927-9.

Mauff K, Steyerberg EW, Nijpels G, van der Heijden AAWA, Rizopoulos D. 2017. Extension of

the association structure in joint models to include weighted cumulative effects. Stat Med.

36(23):3746–3759. doi:10.1002/sim.7385.

Moreno-Betancur M, Carlin JB, Brilleman SL, Tanamas SK, Peeters A, Wolfe R. 2018. Survival

analysis with time-dependent covariates subject to missing data or measurement error: Multiple

Imputation for Joint Modeling (MIJM). Biostatistics. 19(4):479–496.

doi:10.1093/biostatistics/kxx046. http://www.ncbi.nlm.nih.gov/pubmed/29040396.

Papageorgiou G, Mauff K, Tomer A, Rizopoulos D. 2019. An overview of joint modeling of

time-to-event and longitudinal outcomes. Annu Rev Stat Its Appl. 6(1):223–240.

doi:10.1146/annurev-statistics-030718-105048.

https://www.annualreviews.org/doi/10.1146/annurev-statistics-030718-105048.

Paterson AD, Bull SB. 2012. Does familial clustering of risk factors for long-term diabetic

complications leave any place for genes that act independently? J Cardiovasc Transl Res.

5(4):388–398. doi:10.1007/s12265-012-9385-4.

Paterson AD, Waggott D, Boright AP, Hosseini SM, Shen E, Sylvestre MP, Wong I, Bharaj B,

Cleary PA, Lachin JM, et al. 2010. A genome-wide association study identifies a novel major

locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes.

59(2):539–549. doi:10.2337/db09-0653.

Pollack S, Igo RP, Jensen RA, Christiansen M, Li X, Cheng C-Y, Ng MCY, Smith A V, Rossin

EJ, Segrè A V, et al. 2019. Multiethnic genome-wide association study of diabetic retinopathy

using liability threshold modeling of duration of diabetes and glycemic control. Diabetes.

68(2):441–456. doi:10.2337/db18-0567. [accessed 2019 Oct 29].

http://www.ncbi.nlm.nih.gov/pubmed/30487263.

Rizopoulos D. 2010. JM : An R Package for the Joint Modelling of Longitudinal and Time-to-

Event Data. J Stat Softw. 35(9). doi:10.18637/jss.v035.i09. http://www.jstatsoft.org/v35/i09/.

Rizopoulos D. 2012. Joint models for longitudinal and time-to-event data. Chapman and

Hall/CRC. https://www.taylorfrancis.com/books/9781439872871.

Rizopoulos D. 2016. The R package JMbayes for fitting joint models for longitudinal and time-

to-event data using MCMC. J Stat Softw. 72(7). doi:10.18637/jss.v072.i07.

http://www.jstatsoft.org/v72/i07/.

Rizvi AA, Karaesmen E, Morgan M, Preus L, Wang J, Sovic M, Hahn T, Sucheston-Campbell

LE. 2019. gwasurvivr: an R package for genome-wide survival analysis. Bioinformatics.

35(11):1968–1970. doi:10.1093/bioinformatics/bty920.

http://www.ncbi.nlm.nih.gov/pubmed/30395168.

Roshandel D, Gubitosi-Klug R, Bull SB, Canty AJ, Pezzolesi MG, King GL, Keenan HA, Snell-

Bergeon JK, Maahs DM, Klein R, et al. 2018. Meta-genome-wide association studies identify a

locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1

diabetes. Diabetologia. 61(5):1098–1111. doi:10.1007/s00125-018-4555-9.

http://www.ncbi.nlm.nih.gov/pubmed/29404672.

Rubin DB, editor. 1987. Multiple imputation for nonresponse in surveys. Hoboken, NJ, USA:

John Wiley & Sons, Inc. (Wiley Series in Probability and Statistics).

http://doi.wiley.com/10.1002/9780470316696.

Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ,

Williams WW, Sadlier DM, Mäkinen V-P, et al. 2012. New Susceptibility Loci Associated with

Kidney Disease in Type 1 Diabetes. Böger CA, editor. PLoS Genet. 8(9):e1002921.

doi:10.1371/journal.pgen.1002921. http://www.ncbi.nlm.nih.gov/pubmed/23028342.

Scholtens S, Smidt N, Swertz MA, Bakker SJL, Dotinga A, Vonk JM, Van Dijk F, Van Zon

SKR, Wijmenga C, Wolffenbuttel BHR, et al. 2015. Cohort Profile: LifeLines, a three-

generation cohort study and biobank. Int J Epidemiol. 44(4):1172–1180. doi:10.1093/ije/dyu229.

Self S, Pawitan Y. 1992. Modeling a marker of disease progression and onset of disease. In:

AIDS Epidemiology. Boston, MA: Birkhäuser Boston. p. 231–255.

http://link.springer.com/10.1007/978-1-4757-1229-2_11.

Shah A, Laird N, Schoenfeld D. 1997. A random-effects model for multiple characteristics with

possibly missing data. J Am Stat Assoc. 92(438):775. doi:10.2307/2965726.

Sikorska K, Lesaffre E, Groenen PJF, Rivadeneira F, Eilers PHC. 2018. Genome-wide analysis

of large-scale longitudinal outcomes using penalization - GALLOP algorithm. Sci Rep. 8(1).

doi:10.1038/s41598-018-24578-7.

Sobel ME. 1982. Asymptotic confidence intervals for indirect effects in structural equation

models. Sociol Methodol. 13:290. doi:10.2307/270723.

https://www.jstor.org/stable/270723?origin=crossref.

Song X, Davidian M, Tsiatis AA. 2002. A semiparametric likelihood approach to joint modeling

of longitudinal and time-to-event data. Biometrics. 58(4):742–53. doi:10.1111/j.0006-

341x.2002.00742.x. http://www.ncbi.nlm.nih.gov/pubmed/12495128.

Sun L, Dimitromanolakis A, Faye LL, Paterson AD, Waggott D, DCCT/EDIC Research Group,

Bull SB. 2011. BR-squared: a practical solution to the winner's curse in genome-wide scans.

Hum Genet. 129(5):545–52. doi:10.1007/s00439-011-0948-2.

http://www.ncbi.nlm.nih.gov/pubmed/21246217.

Sweeting MJ, Thompson SG. 2011. Joint modelling of longitudinal and time-to-event data with

application to predicting abdominal aortic aneurysm growth and rupture. Biometrical J.

53(5):750–763. doi:10.1002/bimj.201100052.

Tang AM, Tang NS. 2014. Semiparametric Bayesian inference on skew-normal joint modeling

of multivariate longitudinal and survival data. Stat Med. 34(5):824–843. doi:10.1002/sim.6373.

Tang NS, Tang AM, Pan DD. 2014. Semiparametric Bayesian joint models of multivariate

longitudinal and survival data. Comput Stat Data Anal. 77:113–129.

doi:10.1016/j.csda.2014.02.015.

The 1000 Genomes Project Consortium. 2015. A global reference for human genetic variation.

Nature. 526(7571):68–74. doi:10.1038/nature15393.

http://www.ncbi.nlm.nih.gov/pubmed/26432245.

The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive

treatment of diabetes on the development and progression of long-term complications in insulin-

dependent diabetes mellitus. N Engl J Med. 329(14):977–986.

doi:10.1056/NEJM199309303291401. [accessed 2019 Aug 15]. www.nejm.org.

Therneau TM. 2020. A Package for survival analysis in R. R package version 3.2-7, URL

http://CRAN.R-project.org/package=survival. https://cran.r-project.org/package=survival.

Therneau TM, Grambsch PM. 2000. Modeling survival data: extending the Cox model. New

York, NY: Springer New York (Statistics for Biology and Health). [accessed 2019 Aug 8].

https://books.google.ca/books?id=oj0mBQAAQBAJ&printsec=frontcover&dq=therneau+and+gr

ambsch&hl=fr&sa=X&ved=0ahUKEwjZ96antfPjAhWXHM0KHbxCCoAQ6AEILDAA#v=one

page&q=age1&f=false.

Tsiatis AA, Davidian M. 2001. A semiparametric estimator for the proportional hazards model

with longitudinal covariates measured with error. Biometrika. 88(2):447–458.

doi:10.1093/biomet/88.2.447. https://academic.oup.com/biomet/article-

lookup/doi/10.1093/biomet/88.2.447.

Tsiatis AA, Davidian M. 2004. Joint modeling of longitudinal and time-to-event data: An

overview. Stat Sin. 14(3):809–34.

Tsiatis AA, Degruttola V, Wulfsohn MS. 1995. Modeling the relationship of survival to

longitudinal data measured with error. Applications to survival and CD4 counts in patients with

AIDS. J Am Stat Assoc. 90(429):27–37. doi:10.1080/01621459.1995.10476485.

https://about.jstor.org/terms.

Wheeler E, Leong A, Liu C-TT, Hivert M-FF, Strawbridge RJ, Podmore C, Li M, Yao J, Sim X,

Hong J, et al. 2017. Impact of common genetic determinants of Hemoglobin A1c on type 2

diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-

analysis. PLoS Med. 14(9):e1002383. doi:10.1371/journal.pmed.1002383.

http://www.ncbi.nlm.nih.gov/pubmed/28898252.

Wu L, Liu W, Yi GY, Huang Y. 2012. Analysis of longitudinal and survival data: joint

modeling, inference methods, and issues. J Probab Stat. 2012:1–17. doi:10.1155/2012/640153.

http://www.hindawi.com/journals/jps/2012/640153/.

Wulfsohn MS, Tsiatis AA. 1997. A joint model for survival and longitudinal data measured with

error. Biometrics. 53(1):330. doi:10.2307/2533118.

http://www.ncbi.nlm.nih.gov/pubmed/9147598.

Xu J, Zeger SL. 2001. Joint analysis of longitudinal data comprising repeated measures and

times to events. J R Stat Soc Ser C (Applied Stat. 50(3):375–387. doi:10.1111/1467-9876.00241.

https://onlinelibrary.wiley.com/doi/10.1111/1467-9876.00241.

Ye Q, Wu L. 2017. Two-step and likelihood methods for joint models of longitudinal and

survival data. Commun Stat - Simul Comput. 46(8):6019–6033.

doi:10.1080/03610918.2016.1188208. [accessed 2019 Jul 12].

https://www.tandfonline.com/doi/full/10.1080/03610918.2016.1188208.

Ye W, Lin X, Taylor JMG. 2008. Semiparametric modeling of longitudinal measurements and

time-to-event data - A two-stage regression calibration approach. Biometrics. 64(4):1238–1246.

doi:10.1111/j.1541-0420.2007.00983.x.

Young AI, Benonisdottir S, Przeworski M, Kong A. 2019. Deconstructing the sources of

genotype-phenotype associations in humans. Science. 365(6460):1396–1400.

doi:10.1126/science.aax3710. http://science.sciencemag.org/.

Yuen HP, Mackinnon A, Hartmann J, Amminger GP, Markulev C, Lavoie S, Schäfer MR, Polari

A, Mossaheb N, Schlögelhofer M, et al. 2018. Dynamic prediction of transition to psychosis

using joint modelling. Schizophr Res. 202(2018):333–340. doi:10.1016/j.schres.2018.07.002.

https://doi.org/10.1016/j.schres.2018.07.002.

Zhu H, Ibrahim JG, Chi YY, Tang N. 2012. Bayesian influence measures for joint models for

longitudinal and survival data. Biometrics. 68(3):954–964. doi:10.1111/j.1541-

0420.2012.01745.x.

1139

1140

Appendix

Joint likelihood function of the joint model of one longitudinal and one time-to-event trait (L=K=1)

Under the following assumptions (A1-A3),

(A1) $b_i \sim N_2(0, D)$, where $b_i = (b_{i,0}, b_{i,1})^T$ are subject-specific random effects

(A2) $\varepsilon_{i,j} \sim N(0, \sigma^2)$ and $\varepsilon_{i,j} \perp \varepsilon_{i,s}$ between visit times $t_{i,j} \neq t_{i,s}$, with $j \neq s$, for all $1 \leq j \leq J$ and $1 \leq s \leq J$

(A3) $b_i \perp \varepsilon_i$, where $\varepsilon_i = (\varepsilon_{i,1}, \dots, \varepsilon_{i,j}, \dots, \varepsilon_{i,J})^T$, $\varepsilon_i \sim N_J(0, \sigma^2 I_J)$

Then conditional on the random effects b_i and fixed effects Ω, it is appropriate to assume: the repeated measurements in the longitudinal process are independent (Laird and Ware 1982), in other words that the serial correlation is taken into account; and the longitudinal and time-to-event trait models are independent (Ibrahim et al. 2001). Under these conditional independence assumptions, the joint likelihood function of the joint model parameters Ω given the observed data is:

$$L(\Omega|y_i, T_i, \delta_i) = \prod_{i=1}^{N} \int f_1(y_i| b_i, \Omega) \times f_2(T_i, \delta_i | b_i, \Omega) \times f_3(b_i|\Omega) db_i$$

where:

- $f_1(y_i| b_i, \Omega) = (2\pi\sigma^2)^{-J/2} \prod_{j=1}^{J} \exp\left(\frac{(y_{i,j} - y_i^*(t_{i,j}))^2}{2\sigma^2}\right)$

- $f_2(T_i, \delta_i | b_i, \Omega) = [\lambda_i(T_i| b_i, \Omega)]^{\delta_i} S_i(T_i| b_i, \Omega)$, with

- $S_i(T_i| b_i, \Omega) = exp\left[-\int_0^{T_i} \lambda_0(s) exp\{\alpha w_i(s) + \gamma_g g_i\} ds\right]$ and $w_i(t) = f(y_i^*(t))$,

  where $y_i^*(t)$, denotes the lth QT trajectory at time t for $1 \leq l \leq L$ which depends on the fixed and random effects β and b_i. The survival function depends on the whole QT history

of the true unobserved longitudinal process up to time t, noted as $Y_i^*(t)=\{y_i^*(s), 0 \leq s \leq$

$t\}$;

• $f_3(\boldsymbol{b_i}|\boldsymbol{\Omega}) = (2\pi)^{-q/2}|\boldsymbol{D}|^{-1/2}exp\left\{-\frac{1}{2}\boldsymbol{b_i}^T\boldsymbol{D}^{-1}\boldsymbol{b_i}\right\}$, where q is the dimension of the $\boldsymbol{D}$

matrix.

The event indicator δ_i is used to distinguish the contribution of the individuals who experience the

event during the observation period from the individuals who are still at risk up to that time point

but do not experience the event. Individuals who experience the event ($\delta_i = 1$) contribute to the

cumulative hazard function and to the hazard function both evaluated at the T_i; the individuals who

do not experience the event ($\delta_i = 0$) contribute to the hazard function only.

Joint model parameter estimation can be performed by maximization of the full joint likelihood

function directly or by Bayesian computation. Direct maximization of the joint likelihood function

can be performed using the Expectation-Maximization (EM) algorithm, treating the random effects

as missing data (Wulfsohn and Tsiatis 1997). However, integrals with respect of time in the

definition of the survival function, as well as the integral with respect to the $\boldsymbol{b_i}$ do not have an

analytical solution; therefore, numerical approaches, such as adaptive Gauss-Hermit quadrature,

need to be used. Implementations of this model using a maximization of the above joint likelihood

function have been proposed in different R packages (see (Furgal et al. 2019) for a review).

However, as the dimension of the random effects increases, the integral over the random effects

becomes computationally burdensome and Bayesian approaches can be employed instead, where

the random effects are also considered model parameters obtained as a posterior sample and thus

the integral over the random effects is no longer required.

Joint model of multiple longitudinal and multiple time-to-event traits

Joint likelihood function

Extending the previous joint model assumptions (A1-A3) to $L>1$ and $K>1$, we have

(A1) $\boldsymbol{b_i} \sim N_2(0, \boldsymbol{D})$, where $\boldsymbol{b_i} = \left(\boldsymbol{b_{i,1}}, \dots, \boldsymbol{b_{i,l}}, \dots, \boldsymbol{b_{i,L}}\right)^T$ are subject-specific random effects

for all L QTs

(A2) $\boldsymbol{\varepsilon_{i,l}} \sim N_J\left(\boldsymbol{0}, \sigma_l^2 \boldsymbol{I_J}\right)$ for all l^{th} QT with $1 \leq l \leq L$

(A3) $\boldsymbol{b_{i,l}} \perp \boldsymbol{\varepsilon_{i,l}}$ for all l^{th} QT with $1 \leq l \leq L$, and

(A4) $u_i \perp \boldsymbol{b_{i,l}}$, where u_i is a shared subject-specific frailty for k time-to-event traits.

Then, conditional on the random effects $\boldsymbol{b_i}$, the frailty u_i, and fixed effects $\boldsymbol{\Omega}$, we further assume:

$\boldsymbol{b_i}$ accounts for association among the L longitudinal traits (Shah et al. 1997) and association

between the longitudinal and time-to-event outcomes (Ibrahim et al. 2001); and the frailty term

accounts for residual dependence among the time-to-event traits (Hougaard 1995). Under these

conditional independence assumptions, the joint likelihood function of the joint model parameters

$\boldsymbol{\Omega}$ given the observed data is:

$$L(\boldsymbol{\Omega}|\boldsymbol{y_i}, \boldsymbol{T_i}, \boldsymbol{\delta_i}) = \prod_{i=1}^{N} \int f_1(\boldsymbol{y_i}| \boldsymbol{b_i}, \boldsymbol{\Omega}) \times f_2(\boldsymbol{T_i}, \boldsymbol{\delta_i} \mid \boldsymbol{b_i}, u_i, \boldsymbol{\Omega}) \times f_3(\boldsymbol{b_i}|\boldsymbol{\Omega}) \times f_4(u_i|\boldsymbol{\Omega}) \, du_i db_i$$

where:

• $(\boldsymbol{T_i}, \boldsymbol{\delta_i}) = ((T_{i,1}, \delta_{i,1}), \dots, (T_{i,k}, \delta_{i,k}), \dots, (T_{i,K}, \delta_{i,K}))^T$ is defined as the vector of K stacked

time-to-event outcomes for individual i,

• $f_1(\boldsymbol{y}_i|\boldsymbol{b}_i,\boldsymbol{\Omega}) = \prod_{l=1}^{L} f(\boldsymbol{y}_{i,l}|\boldsymbol{b}_{i,l},\boldsymbol{\Omega}_l)$ with $f(\boldsymbol{y}_{i,l}|\boldsymbol{b}_{i,l},\boldsymbol{\Omega}_l) =$

$\quad (2\pi\sigma_l^2)^{-\frac{J}{2}} exp\left[-\frac{1}{2\sigma_l^2}\prod_{j=1}^{J}(y_{i,j,l} - y_{i,l}^*(t_{i,j}))^2\right]$

• $f_2(\boldsymbol{T}_i,\boldsymbol{\delta}_i | \boldsymbol{b}_i, u_i, \boldsymbol{\Omega}) = \prod_{k=1}^{K}\left[\lambda_{i,k}(T_{i,k}|\boldsymbol{b}_i, u_i, \boldsymbol{\Omega})\right]^{\delta_{i,k}} S_{i,k}(T_{i,k}|\boldsymbol{b}_i, u_i, \boldsymbol{\Omega})$, with

$\quad S_{i,k}(T_{i,k}|\boldsymbol{b}_i, u_i, \boldsymbol{\Omega}) = exp\left[-\int_0^{T_{i,k}}\lambda_{0,k}(s)exp\{\sum_{l=1}^{L}\alpha_{l,k}w_{i,l,k}(s)) + \gamma_{g,k}g_i + u_i\}\,ds\right]$ and

$\quad w_{i,l,k}(s) = f_{l,k}\left(y_{i,l}^*(t)\right),$ where $y_{i,l}^*(t),$ denotes the lth QT trajectory at time t for $1 \le l \le$

$\quad L$ which depends on the fixed and random effects $\boldsymbol{\beta}_l$ and $\boldsymbol{b}_{i,l}$.

• $f_3(\boldsymbol{b}_i|\boldsymbol{\Omega}) = (2\pi)^{-q/2}|\boldsymbol{D}|^{-\frac{1}{2}} exp\left[-\frac{1}{2}\boldsymbol{b}_i^T\boldsymbol{D}^{-1}\boldsymbol{b}_i\right],$ where q is the dimension of the $\boldsymbol{D}$ matrix

• $f_4(u_i|\boldsymbol{\Omega}) = \frac{u_i^{a-1}exp\,(-u_i/b)}{\Gamma(a)b^a},$ i.e. we assume $u_i{\sim}\text{Gamma}(a, b)$ with $u_i > 0, a$ corresponds

$\quad$ to the shape parameter and b to the scale parameter, and $a, b{>}0.$ $\Gamma(a)$ is the gamma function

$\quad$ evaluated at a.

We are not aware of any existing implementations of full likelihood maximization of the extended

model in the literature. Calculation of the full likelihood requires multivariate integration with

respect to the random effects distribution, which can lead to demanding computation. When the

random effect vector $\boldsymbol{b}_i,$ has a small dimension, say less than 3, the integral can be evaluated via

Gaussian quadrature which approximates the integral by a weighted sum of the target function

evaluated at pre-specified sample points. However, when the dimension is larger, it is demanding

to calculate the integrals with satisfactory approximation accuracy. Although a full likelihood

specification enables rigorous study of asymptotic properties, its large sample approximation may

not be accurate when sample size is small. In comparison, the Bayesian paradigm does not require

asymptotic approximations, but the design of an efficient sampling algorithm to study the posterior

distribution is challenging. Because of these limitations, we implement a two-stage approach to

estimation of fixed effect parameters in the extended multi-trait model that is reasonable for the

GWAS application of interest; in particular the longitudinal measurements in DCCT are taken

according to a pre-specified schedule and are not terminated by the observation of diabetes

complications, loss to follow-up and mortality are minimal, censoring is administrative, and each

individual has a dense and nearly complete set of measurements.

Likelihood functions under the two-stage approximation

Let $\boldsymbol{\Omega}_{Long}$ and $\boldsymbol{\Omega}_{Surv}$ be the vectors containing all fixed parameters from the longitudinal and

time-to-event sub-models respectively.

Stage 1*:* Multivariate mixed model

1230
$$L\left(\boldsymbol{\Omega}_{Long}|\boldsymbol{y}_i\right) = \prod_{i=1}^{N} \int_{\boldsymbol{b}_i} f_1\left(\boldsymbol{y}_i\middle|\,\boldsymbol{b}_i,\,\boldsymbol{\Omega}_{Long}\right) \times f_3\left(\boldsymbol{b}_i\middle|\,\boldsymbol{\Omega}_{Long}\right) d\boldsymbol{b}_i$$

Where:

• $f_1\left(\boldsymbol{y}_i\middle|\,\boldsymbol{b}_i,\boldsymbol{\Omega}_{Long}\right) = \prod_{l=1}^{L} f\left(\boldsymbol{y}_{i,j,l}\middle|\,\boldsymbol{b}_i,\boldsymbol{\Omega}_{Long}\right)$ with $f\left(\boldsymbol{y}_{i,l}\middle|\,\boldsymbol{b}_i,\boldsymbol{\Omega}_{Long}\right) =$

$(2\pi\sigma_l^2)^{-\frac{J}{2}} exp\left[-\frac{1}{2\sigma_l^2}\prod_{j=1}^{J}(y_{i,j,l} - y_{i,l}^*(t_{i,j}))^2\right]$

• $f_3\left(\boldsymbol{b}_i\middle|\boldsymbol{\Omega}_{Long}\right) = (2\pi)^{-q/2}|\boldsymbol{D}|^{-\frac{1}{2}} exp\left[-\frac{1}{2}\boldsymbol{b}_i^T\boldsymbol{D}^{-1}\boldsymbol{b}_i\right]$ where q is the dimension of the $\boldsymbol{D}$

matrix.

The fixed-effect and random-effect parameters are estimated jointly for all longitudinal traits using

all available repeated measurements, without using the time-to-event information. Then fitted

trajectory values are obtained by plugging the parameter estimates into:

$$y_{i,l}^*(t) = X_i(t)\beta_l + Z_i(t)b_{i,l}$$

where $X_i(t) = (1, t, g_i)$ and $Z_i(t) = (1, t)$

Stage 2: Multivariate Cox PH model adjusted for fitted trajectory values for the vector of L

longitudinal outcomes

$$L\left(\Omega_{Surv}|T_i, \delta_i, \widehat{w_i(T_i)}\right) = \prod_{i=1}^{N} \int_{u_i} f_2\left(T_i, \delta_i \mid u_i, \widehat{w_i(T_i)}, \Omega_{Surv}\right) \times f_4(u_i|\Omega_{Surv}) \times du_i$$

With:

$$f_2\left(T_i, \delta_i \mid u_i, \widehat{w_i(T_i)}, \Omega_{Surv}\right) =$$

$$\prod_{k=1}^{K}\left[\lambda_{i,k}\left(T_{i,k}\mid u_i, \widehat{w_{i,k}(T_{i,k})}, \Omega_{Surv}\right)\right]^{\delta_{i,k}} S_{i,k}\left(T_{i,k}\mid u_i, \widehat{w_{i,k}(T_{i,k})}, \Omega_{Surv}\right), \text{ and}$$

$$S_{i,k}\left(T_{i,k}\mid u_i, \widehat{w_{i,k}(T_{i,k})}, \Omega_{Surv}\right) = exp\left[-\int_0^{T_{i,k}}\lambda_{i,0}(s)exp\{\sum_{l=1}^{L}\alpha_{l,k}\ \widehat{w_{i,l,k}(s)} + \gamma_{g,k}\ g_i + u_i\}ds\right],$$

where $\widehat{w_{i,l,k}(s)}$ is obtained by plugging fitted trajectory values into $w_{i,l,k}(t) = f_{l,k}\left(y_{i,l}^*(t)\right)$.

Unlike the *joint likelihood function*, where the shared random effects b_i account for the

dependencies between the longitudinal and the time-to-event traits, the two-stage approach

accounts for the dependencies between the longitudinal and time-to-event traits via the fitted

values of the longitudinal trajectories. This approximation can produce biased estimates and/or

underestimated standard errors for longitudinal and survival model parameters, when there is non-

random censoring of the longitudinal trait values due to the occurrence of an event or from

informative dropout (Ye et al. 2008; Albert and Shih 2010), and because of propagation errors of

Stage 1 parameter estimates into Stage 2 (Wulfsohn and Tsiatis 1997). Under longitudinal model

mis-specification and estimation bias, the conditional independence assumption can fail, undermining the accurate of trajectory estimates. Because the time-to-event processes are related to length of follow-up, informative missingness/dropouts can lead to differential follow-up between subjects with and without an event, and thus the random effects $\boldsymbol{b_i}$ can depend on the event times (e.g. patients who have an event early are more likely to have positive random slopes). However, as we show in the simulation studies, in absence of model mis-specification and informative dropouts/missingness, this approach has low bias and is computationally feasible for genetic association studies.

Fig. 1. Directed acyclic graph (DAG) illustrating the joint model parameters to characterize the direct SNP effect on the time-to-event trait and the indirect SNP effect via the intermediate longitudinal QT associated with the time-to-event trait. Figure adapted from (Ibrahim et al. 2010) which proposed a general joint model formulation for one longitudinal QT and one time-to-event trait to address questions specific to testing for treatment effects in randomized-controlled clinical trials.

Fig. 2. Proposed joint modelling approach for characterization of complex genetic architecture of multiple disease progression

Multivariate mixed-effects sub-model for all L longitudinal QT ($1 \leq l \leq L$)

Smoothed longitudinal trajectory for the lth QT

$$y_{i,l}^*(t) = \beta_{0,l} + b_{i,0,l} + (\beta_{1,l} + b_{i,1,l})t + \beta_{g,l}g_i \quad \text{(Equation 4)}$$

- latent and continuous process
- various shapes (linear/non-linear)
- smoothed, accounts for within-subject random variability
- $\beta_{g,l}$: SNP effect on the lth QT
- account for shared and/or trait-specific covariates
- $b_i \sim N_{2L}(\mathbf{0}, \mathbf{D})$: subject deviation from average trajectories
- $\mathbf{D}$: dependencies within and between L QT(s)

Measured longitudinal values for the lth QT

$$y_{i,l} = y_{i,l}^*(t_i) + \varepsilon_{i,l} \text{ with } \varepsilon_{i,l} \sim N_J(0, \Sigma_l) \quad \text{(Equation 5)}$$

- intermittently measured at scheduled visit times (t_i)
- within-subject random variability (i.e. biological variation)
- potential missing values

Time-dependent association structures

$$w_{i,l,k}(t) = f_{l,k}(y_{i,l}^*(t)), \; 1 \leq l \leq L, 1 \leq k \leq K$$

- $f_{l,k}(y_{i,l}^*(t))$, **functional dependence** between l^{th} & k^{th} traits, based on prior knowledge
- accounts for the **indirect** SNP effect via the lth QT

Proportional Hazards frailty sub-model for K time-to-event traits ($1 \leq k \leq K$)

$$\lambda_{i,k}(t) = \lambda_{0,k}(t) \times exp\{\textstyle\sum_{l=1}^{L} \alpha_{l,k}w_{i,l,k}(t) + \gamma_{g,k}g_i + u_i\} \quad \text{(Equation 6)}$$

- $\gamma_{g,k}$: direct SNP effect on the kth time-to-event trait
- $\alpha_{l,k}$: association between the lth QT & the kth time-to-event trait
- u_i: accounts for unexplained dependencies between K traits
- accounts for shared and/or trait-specific covariates

Classification of SNP associations for the (l, k) QT/TTE pair ($\alpha_{l,k} \neq 0$):

- Indirect: $\beta_{g,l} \neq 0$ & $\gamma_{g,k} = 0$
- Direct: $\beta_{g,l} = 0$ & $\gamma_{g,k} \neq 0$
- Direct & Indirect: $\beta_{g,l} \neq 0$ & $\gamma_{g,k} \neq 0$

Fig. 3. Realistic DCCT-data-based causal genetic scenario

We generated $R=1000$ replicates of $N=667$ DCCT individuals with $M=5$ causal variants and $K=2$ time-to-event traits simulated under this causal genetic scenario, and $R=1000$ replicates of $M=5$ SNPs (with same MAF as the causal ones) simulated under a *global null* genetic scenario where none of the SNPs is associated with any traits. The effects of gender on SBP, and of T1D duration at baseline on both time-to-T1DC traits are not represented in this figure, but are included in the data generating model, see File S2 (sections 2 and 3) for details.

Fig. 4. Illustration of the procedure developed for DCCT-based simulation study under the scenario from Fig. 3

For each individual i, with $\{t_i, y_{i,1}, y_{i,2}\}$ observed in DCCT, the algorithm simulate: latent longitudinal QT values for U ($y_{i,u}$), genetic data at M causal SNPs (with p, the specified vector of MAFs) and time-to-event data ($T_{i,k}, \delta_{i,k}$) for $K=2$ time-to-T1DC traits. The genetic data are simulated under Hardy-Weinberg and linkage equilibrium assumptions. SNPs with indirect effects are simulated from a multinomial distribution with calculated conditional genotype probabilities for individual i ($\pi_{g_i=0}, \pi_{g_i=1}, \pi_{g_i=2}$) based on $y_{i,l}$. Each $y_{i,l}$ is assumed to follow a multivariate normal distribution with $X_{i,l}$ and $Z_{i,l}$ the specified fixed and random effect design matrices in longitudinal trait models and $\Omega_l = \{\beta_l, D_l, \sigma_l^2\}$ the vector of specified parameter values for each lth QT. SNPs with direct effects are simulated from the population probabilities, that depend only on the MAF. The specified hazard function for each kth time-to-event trait depends on the effects of the longitudinal QT trajectories and on the SNPs with direct effects in $\eta_{i,k}$, with $\eta_{i,1} = \gamma_{g,1} SNP2_i + \alpha_{1,1} y_{i,1}^*(t)$ for DR and $\eta_{i,2} = \gamma_g SNP4_i + \gamma'_g SNP5_i + \alpha_{1,2} y_{i,1}^*(t) + \alpha_{2,2} y_{i,2}^*(t)$ for DN, as well as the effect of the shared latent QT trajectory $y_{i,u}^*(t)$ used to induce some dependencies between the time-to-event traits. We define Γ_k as the vectors of specified parameter values for each kth time-to-event trait. The uncensored event time $T_{i,k}^*$, is simulated by calculating the inverse of the cumulative specified hazard function using the Brent univariate root-finding method (Brent 2013; Crowther and Lambert 2013). To simplify the exposition of the simulation procedure, we ignore the effects of the sex on SBP and of the T1D duration on both T1DC traits, but they were included in the data generating model, see File S2 for details. Parameters for the causal genetic scenario are shown in Fig. 3 and File S2 (section 4)

Fig. 5. Classification of direct and/or indirect SNP associations in the DCCT Genetics Study data.

(**A**) Scatter plots of the *P*-values (-log10) for tests of $\beta_{g,l}$ (H0: $\beta_{g,l} = 0$ vs H1 $\beta_{g,l} \neq 0$) on the *X* axis and $\gamma_{g,k}$ (H0: $\gamma_{g,k} = 0$ vs H1: $\gamma_{g,k} \neq 0$) on the *Y* axis for HbA1c/DR, HbA1c/DN and SBP/DN trait pairs. Significance levels $P^* = 1.7 \times 10^{-4}$ and $P^* = 0.05$ are indicated by red and grey horizontal and vertical dashed lines. (**B**) and (**C**) represent association results for rs10810632 and rs1358030 detected as indirect associations at $P^* = 1.7 \times 10^{-4}$. Left panels present results from separate analysis of each trait (*ie.* longitudinal model for each QT and Cox PH time-to-event model without adjusting for the longitudinal traits) as used in naïve discovery GWAS; and right panels show results from the joint model with bootstrap 95% confidence intervals for the direct and indirect SNP effects. Results are presented using time-weighted cumulative HbA1c effects on T1DC traits.

Fig. 6. Change in classification results for rs10810632 with HbA1c/DR to increasing sample size (A) and to the Winner's curse bias for the SNP effect on HbA1c (B) investigated using parametric resampling.

We used parametric resampling (File S3, section 6) to draw datasets with sample size up to five times the DCCT sample size of $N=516$, and then extrapolated the classification results beyond $N=2580$. The X axes of (**A**) and (**B**), show the P-values (-log10) for the test of rs10810632 effect on HbA1c (H0: $\beta_{g,1} = 0$ vs H1 $\beta_{g,1} \neq 0$)), while the Y axes show the P-values (-log10) for the test of rs10810632 effect on DR (H0: $\gamma_{g,1} = 0$ vs H1: $\gamma_{g,1} \neq 0$) for the sample sizes investigated (shown by different colors). We fitted a regression line on each plot to project the trend of the classification beyond $N=2580$ individuals. These plots illustrate the corresponding shift in classification of rs10810632 association with DR as indirect via HbA1c towards classification as both indirect and direct association. Complete results with HbA1c/DN are shown in File S3 (section 6).

| | | SNP association with the longitudinal risk factor l | |
		$P_{\beta_{g,l}} \leq P^*_{\beta_g}$	$P_{\beta_{g,l}} > P^*_{\beta_g}$
SNP association with the time-to-event trait k	$P_{\gamma_{g,k}} \leq P^*_{\gamma_g}$	Direct & Indirect $\beta_{g,l} \neq 0$ AND $\gamma_{g,k} \neq 0$	Direct $\beta_{g,l} = 0$ AND $\gamma_{g,k} \neq 0$
	$P_{\gamma_{g,k}} > P^*_{\gamma_g}$	Indirect $\beta_{g,l} \neq 0$ AND $\gamma_{g,k} = 0$	Not Direct & Not Indirect $\beta_{g,l} = 0$ AND $\gamma_{g,k} = 0$

$P_{\beta_{g,l}}$ and $P_{\gamma_{g,k}}$ are P-values from Wald tests ($1df$) for each of SNP effects $\beta_{g,l}$ and $\gamma_{g,k}$. For the former, we test H0: $\beta_{g,l} = 0$ vs H1: $\beta_{g,l} \neq 0$. For the latter, H0: $\gamma_{g,k} = 0$ vs H1: $\gamma_{g,k} \neq 0$. $P^*_{\beta_g}$ and $P^*_{\gamma_g}$ are the corresponding classification thresholds (see Materials and Methods for details). For example, if the H0: $\beta_{g,l} = 0$ is rejected and H0: $\gamma_{g,k} = 0$ is rejected by the corresponding test statistics, then the SNP is classified as being both indirectly and directly associated with the time-to-event trait k. The classification procedure is based on the two separate test statistics and does not require a joint test statistic of the overall SNP effect; it thus partitions the two-dimensional parameter space into four mutually exclusive quadrants. In the simulations and application, we use $P^* = P^*_{\beta_g} = P^*_{\gamma_g}$, although different thresholds can be specified for $P^*_{\beta_g}$ and $P^*_{\gamma_g}$.

Table 1. Procedure to classify a SNP as having an association with a time-to-event trait k, indirectly through an associated longitudinal risk factor l and/or directly with trait k, based on hypothesis tests of SNP effects $\beta_{g,l}$ and $\gamma_{g,k}$.

SNPs[1]	Analysis Models	Global null at $P*=5\%$				Genetic alternative at $P*=5\%$			
		HbA1c	SBP	DR	DN	HbA1c	SBP	DR	DN
SNP1 (MAF= 30%)		$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\gamma_{g,2}=0$	$\boldsymbol{\beta_{g,1}=0.7}$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\gamma_{g,2}=0$
	JM-cmp	5.2	5.8	4.4	4.8	**100**	5.1	4.1	5.4
	JM-mis	5.2	5.8	3.6	4.9	**100**	5.1	4.2	4.6
	JM-sep(l=1,2; k=1)	5.2	5.8	3.8	.	**100**	5.1	4.7	.
	JM-sep(l=1,2; k=2)	5.2	5.8	.	5.2	**100**	5.1	.	4.6
	JM-sep(l=1; k=1)	5.6	.	4.0	.	**100**	.	4.6	.
	JM-sep(l=1; k=2)	5.6	.	.	4.6	**100**	.	.	5.7
	JM-sep(l=2; k=2)	.	5.9	.	4.6	**.**	5.2		11.2
SNP2 (MAF= 10%)		$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\gamma_{g,2}=0$	$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\boldsymbol{\gamma_{g,1}=0.8}$	$\gamma_{g,2}=0$
	JM-cmp	5.5	6.0	5.8	3.9	6.6	5.4	**100**	3.9
	JM-mis	5.5	6.0	4.5	3.8	6.6	5.4	**100**	4.6
	JM-sep(l=1,2; k=1)	5.5	6.0	5.0	.	6.6	5.4	**100**	.
	JM-sep(l=1,2; k=2)	5.5	6.0	.	4.4	6.6	5.4	**.**	5.2
	JM-sep(l=1; k=1)	5.0	.	5.0	.	6.1	.	**100**	.
	JM-sep(l=1; k=2)	5.0	.	.	5.1	6.1	.	**.**	4.6
	JM-sep(l=2; k=2)	.	6.7	.	4.9	.	5.2	**.**	4.7
SNP3[1] (MAF= 40%)		$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\gamma_{g,2}=0$	$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\gamma_{g,2}=0$
	JM-cmp	4.0	6.7	4.3	4.5	4.5	4.6	4.7	3.8
	JM-mis	4.0	6.7	4.6	3.9	4.5	4.6	89.9	58.4
	JM-sep(l=1,2; k=1)	4.0	6.7	4.7	.	4.5	4.6	89.7	.
	JM-sep(l=1,2; k=2)	4.0	6.7	.	4.4	4.5	4.6	.	57.7
	JM-sep(l=1; k=1)	4.1	.	4.6	.	4.8	.	89.7	.
	JM-sep(l=1; k=2)	4.1	.	.	4.6	4.8	.	.	33.0
	JM-sep(l=2; k=2)	.	6.5	.	4.8	.	4.4	.	56.4
SNP4 (MAF= 30%)		$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\gamma_{g,2}=0$	$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\boldsymbol{\gamma_{g,2}=0.7}$
	JM-cmp	4.8	6.3	3.9	4.9	5.4	4.8	6.0	**100**
	JM-mis	4.8	6.3	4.9	4.7	5.4	4.8	5.4	**100**
	JM-sep(l=1,2; k=1)	4.8	6.3	4.9	.	5.4	4.8	5.1	**.**
	JM-sep(l=1,2; k=2)	4.8	6.3	.	5.1	5.4	4.8	.	**99.9**
	JM-sep(l=1; k=1)	5.0	.	4.6	.	6.1	.	5.1	**.**
	JM-sep(l=1; k=2)	5.0	.	.	5.0	6.1	.	.	**93.9**
	JM-sep(l=2; k=2)	.	5.6	.	4.8	.	4.8	.	**99.9**
SNP5 (MAF= 20%)		$\beta_{g,1}=0$	$\beta_{g,2}=0$	$\gamma_{g,1}=0$	$\gamma_{g,2}=0$	$\beta_{g,1}=0$	$\boldsymbol{\beta_{g,2}=7}$	$\gamma_{g,1}=0$	$\boldsymbol{\gamma_{g,2}=0.4}$
	JM-cmp	5.0	5.5	4.7	5.6	2.8	**100**	5.5	**66.4**
	JM-mis	5.0	5.5	4.6	4.5	2.8	**100**	4.6	**64.5**
	JM-sep(l=1,2; k=1)	5.0	5.5	5.2	.	2.8	**100**	4.8	**.**
	JM-sep(l=1,2; k=2)	5.0	5.5	.	5.0	2.8	**100**	.	**63.2**
	JM-sep(l=1; k=1)	5.1	.	5.3	.	2.8	**.**	4.6	**.**
	JM-sep(l=1; k=2)	5.1	.	.	4.9	2.8	**.**	.	**100**
	JM-sep(l=2; k=2)	.	5.6	.	5.4	.	**100**	.	**64.9**

[1]Except for JM-cmp, none of the analyses account for indirect genetic pathways via the longitudinal risk factor U. This translates into elevated T1E in the direct genetic effects $\gamma_{g,k}$ for both time-to-T1DC traits.

Table 2. Empirical type-I error and power (%) for SNP hypothesis tests of each of $\beta_{g,l}$ and $\gamma_{g,k}$ based on the complete joint model and compared models, assessed using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under *global genetic null* and *genetic alternative* simulation scenarios.

Values are computed for each SNP and each genetic association parameter as the proportion of replicates that reject the null hypothesis at significance threshold $P*$=0.05. Results at other significance levels $P*$, and also for CM-obs, are shown in File S2, under the global null scenario at $P* \leq 0.01$ (section 7), and under the alternative genetic scenario at $P^* \leq 10^{-5}$ (section 8).

Table 3. Classification frequencies for SNP1 association with each of the QT/time-to-event trait pairs based on the complete joint model and compared models at significance threshold $P^*=0.05$, using $R=1000$ replicates of $N=667$ DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

SNP	Trait pairs	Analysis Model	Mean Bias[1]		Mean Bootstrap SE's and Correlation[2]			Classification frequencies (%) Expected[3] (above) vs Empirical Values[4]			
SNP1 (MAF= 30%)	HbA1c(l=1)/ DR(k=1)		$\beta_{g,1}=0.7$	$\gamma_{g,1}=0$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,1}}}$	$\widehat{\rho_{1,1}}$	**Indirect**	Direct	Direct & Indirect	Not Direct & Not Indirect
								95.0	**0**	**5.0**	**0**
		JM-cmp		0.002		0.009	-0.003	**95.9**	0	4.1	0
		JM-mis	-0.051	<0.001	0.006	0.010	-0.002	**95.8**	0	4.2	0
		JM-sep(l=1,2; k=1)		<0.001		0.008	-0.002	**95.3**	0	4.7	0
		JM-sep(l=1; k=1)	-0.047	<0.001	0.006	0.008	-0.002	**95.4**	0	4.6	0
		CM-obs	-0.051	0.032	0.006	0.009	0.041	**93.6**	0	6.4	0
	HbA1c(l=1)/ DN(k=2)		$\beta_{g,1}=0.7$	$\gamma_{g,2}=0$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{1,2}}$	**Indirect**	Direct	Direct & Indirect	Not Direct & Not Indirect
								95.0	**0**	**5.0**	**0**
		JM-cmp		-0.011		0.021	-0.012	**94.6**	0	5.4	0
		JM-mis	-0.051	-0.014	0.006	0.024	-0.010	**95.4**	0	4.6	0
		JM-sep(l=1,2; k=2)		-0.011		0.021	-0.009	**95.4**	0	4.6	0
		JM-sep(l=1; k=2)	-0.047	-0.004	0.006	0.019	-0.005	**94.3**	0	5.7	0
		CM-obs	-0.051	0.018	0.006	0.016	0.018	**94.3**	0	5.7	0
	SBP(l=2)/ DN(k=2)		$\beta_{g,2}=0$	$\gamma_{g,2}=0$	$\widehat{\sigma_{\beta_{g,2}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{2,2}}$	Indirect	Direct	Direct & Indirect	**Not Direct & Not Indirect**
								4.75	4.75	0.25	90.25
		JM-cmp		-0.011		0.021	-0.021	5.0	5.3	0.1	**89.6**
		JM-mis	-0.053	-0.014	0.233	0.024	-0.012	5.1	4.6	0	**90.3**
		JM-sep(l=1,2; k=2)		-0.011		0.021	-0.009	5.1	4.6	0	**90.3**
		JM-sep(l=2; k=2)	-0.053	0.095	0.232	0.019	-0.007	4.3	10.3	0.9	**84.5**
		CM-obs	-0.053	0.018	0.233	0.016	0.313	4.5	5.1	0.6	**89.8**

[1]Mean Bias in the SNP1 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

[2]Mean Bootstrap SE's, $\sigma_{\beta_{g,l}}$ and $\sigma_{\gamma_{g,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and mean correlation $\rho_{l,k}$ over the $R=1000$ replicates.

[3]*Expected* classification frequencies (%) for each category of association calculated as the probability to classify SNP1 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, under the assumption that $\widehat{\mathbf{Z}_g} = \left(\widehat{Z_{\beta_{g,l}}}, \widehat{Z_{\gamma_{g,k}}}\right)^T$, constructed from the SNP effect estimates ($\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$) and their bootstrap standard errors ($\widehat{\sigma_{\beta_{g,l}}}$ and $\widehat{\sigma_{\gamma_{g,k}}}$) as $\widehat{Z_{\beta_{g,l}}} = \widehat{\beta_{g,l}} / \widehat{\sigma_{\beta_{g,l}}}$ and $\overline{Z_{\gamma_{g,k}}} = \widehat{\gamma_{g,k}} / \widehat{\sigma_{\gamma_{g,k}}}$ from JM-cmp, asymptotically follows a bivariate normal distribution, that is $\widehat{\mathbf{Z}_g} \sim N_2(E[\mathbf{Z}_g], \mathbf{H})$, where $E[\mathbf{Z}_g]$ is the vector of expectations, and $\mathbf{H} = \begin{pmatrix} 1 & \rho_{l,k} \\ \rho_{l,k} & 1 \end{pmatrix}$ with $\rho_{l,k} = Cor\left(Z_{\beta_{g,l}}, Z_{\gamma_{g,k}}\right) = \sigma_{\beta_{g,l}\gamma_{g,k}} / (\sigma_{\beta_{g,l}} \times \sigma_{\gamma_{g,k}})$ and $\sigma_{\beta_{g,l}\gamma_{g,k}}$, the covariance between $\beta_{g,l}$ and $\gamma_{g,k}$ (See File S2, section 9 for details).

[4]Empirical classification frequencies (shown as a percentage, %) for each SNP association under the *alternative* genetic simulation for $\beta_{g,l}$ and $\gamma_{g,k}$ hypothesis tests using the procedure described in Table 1 at $P^* = P_\beta^* = P_\gamma^* = 0.05$. The results for the correct classification category under the *alternative genetic* simulation scenario from Fig. 3 are shown in bold. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11)

Table 4. Classification frequencies for SNP2 association with each QT/time-to-event trait pairs based on the complete joint model and compared models at significance threshold P^*=0.05, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

SNP	Trait pairs	Analysis Model	Mean Bias[1]		Mean Bootstrap SE's and Correlation[2]			Classification frequencies[3] (%) Expected (above) vs Empirical Values			
			$\beta_{g,1}$=0	$\gamma_{g,1}$=**0.8**	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,1}}}$	$\widehat{\rho_{1,1}}$	Indirect	**Direct**	Direct & Indirect	Not Direct & Not Indirect
								0	**95.0**	**5.0**	**0**
SNP2 (MAF=10%)	HbA1c(l=1)/ DR(k=1)	JM-cmp		0.003		0.015	-0.005	0	**93.4**	6.6	0
		JM-mis	-0.003	-0.023	0.014	0.019	-0.006	0	**93.4**	6.6	0
		JM-sep(l=1,2; k=1)		-0.099		0.015	-0.007	0	**93.4**	6.6	0
		JM-sep(l=1; k=1)	-0.003	-0.099	0.014	0.015	-0.006	0	**93.9**	6.1	0
		CM-obs	-0.003	-0.077	0.014	0.017	0.038	0	**93.4**	6.6	0
			$\beta_{g,1}$=0	$\gamma_{g,2}$=0	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{1,2}}$	Indirect	Direct	Direct & Indirect	**Not Direct & Not Indirect**
								4.75	**4.75**	**0.25**	**90.25**
	HbA1c(l=1)/ DN(k=2)	JM-cmp		<0.001		0.043	-0.010	6.4	3.7	0.2	**89.7**
		JM-mis	-0.003	-0.003	0.014	0.048	-0.011	6.3	4.3	0.3	**89.1**
		JM-sep(l=1,2; k=2)		0.002		0.042	-0.011	6.2	4.8	0.4	**88.6**
		JM-sep(l=1; k=2)	-0.003	-0.006	0.011	0.038	0.011	6.1	4.6	0	**89.3**
		CM-obs	-0.003	-0.004	0.014	0.034	0.023	6.6	4.5	0	**88.9**
			$\beta_{g,2}$=0	$\gamma_{g,2}$=0	$\widehat{\sigma_{\beta_{g,2}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{2,2}}$	Indirect	Direct	Direct & Indirect	**Not Direct & Not Indirect**
								4.75	**4.75**	**0.25**	**90.25**
	SBP(l=2)/ DN(k=2)	JM-cmp		<0.001		0.043	-0.018	5.4	3.9	0	**90.7**
		JM-mis	-0.004	-0.003	0.513	0.048	-0.012	5.4	4.6	0	**90.0**
		JM-sep(l=1,2; k=2)		0.002		0.042	-0.008	5.3	5.1	0.1	**89.5**
		JM-sep(l=2; k=2)	-0.004	0.001	0.512	0.042	-0.005	5.0	4.5	0.2	**90.3**
		CM-obs	-0.004	-0.004	0.513	0.034	0.330	5.0	4.1	0.4	**90.5**

[1]Mean Bias in the SNP2 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

[2]Mean Bootstrap SE's, $\sigma_{\beta_{g,l}}$ and $\sigma_{\gamma_{g,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the R=1000 replicates.

[3]*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP2 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

Table 5. Classification frequencies for SNP4 association with each pair of QT/time-to-event traits based on the complete joint model and compared models at significance threshold $P^*=0.05$, using $R=1000$ replicates of $N=667$ DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

SNP	Trait pairs	Analysis Model	Mean Bias[1]		Mean Bootstrap SE's and Correlation[2]			Classification frequencies[3] (%) Expected (above) vs Empirical Values			
			$\beta_{g,1}=0$	$\gamma_{g,1}=0$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,1}}}$	$\widehat{\rho_{1,1}}$	Indirect	Direct	Direct & Indirect	**Not Direct & Not Indirect**
								4.75	**4.75**	**0.25**	**90.25**
SNP4 (MAF= 30%)	HbA1c($l=1$)/ DR($k=1$)	JM-cmp		-0.001		0.007	<0.001	4.9	5.5	0.5	**89.1**
		JM-mis	0.001	0.001	0.006	0.009	-0.003	5.0	5.0	0.4	**89.6**
		JM-sep($l=1,2$; $k=1$)		0.001		0.007	-0.003	5.1	4.8	0.3	**89.8**
		JM-sep($l=1$; $k=1$)	0.001	0.001	0.006	0.007	-0.002	5.7	4.7	0.4	**89.2**
		CM-obs	0.001	0.001	0.006	0.008	0.038	5.0	4.2	0.4	**90.4**
			$\beta_{g,1}=0$	$\gamma_{g,2}=\mathbf{0.7}$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{1,2}}$	Indirect	**Direct**	Direct & Indirect	Not Direct & Not Indirect
								0	**94.98**	**5.0**	**0.02**
	HbA1c($l=1$)/ DN($k=2$)	JM-cmp		-0.014		0.017	-0.010	0	**94.6**	5.4	0
		JM-mis	0.001	-0.028	0.006	0.019	-0.010	0	**94.6**	5.4	0
		JM-sep($l=1,2$; $k=2$)		-0.076		0.017	-0.009	0	**94.5**	5.4	0.1
		JM-sep($l=1$; $k=2$)	0.001	-0.281	0.006	0.015	0.007	0.3	**88.1**	5.8	5.8
		CM-obs	0.001	-0.216	0.006	0.013	0.025	0	**93.5**	5.4	1.1
			$\beta_{g,2}=0$	$\gamma_{g,2}=\mathbf{0.7}$	$\widehat{\sigma_{\beta_{g,2}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{2,2}}$	Indirect	**Direct**	Direct & Indirect	Not Direct & Not Indirect
								0	**94.98**	**5.0**	**0.02**
	SBP($l=2$)/ DN($k=2$)	JM-cmp		-0.014		0.017	-0.026	0	**95.2**	4.8	0
		JM-mis	0.012	-0.028	0.215	0.019	-0.021	0	**95.2**	4.8	0
		JM-sep($l=1,2$; $k=2$)		-0.076		0.017	-0.020	0	**95.1**	4.8	0.1
		JM-sep($l=2$; $k=2$)	0.012	-0.088	0.215	0.016	-0.019	0	**95.1**	4.8	0.1
		CM-obs	0.012	-0.216	0.215	0.013	0.332	0.1	**94.2**	4.7	1.0

[1]Mean Bias in the SNP4 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

[2]Mean Bootstrap SE's, $\sigma_{\beta_{g,l}}$ and $\sigma_{\gamma_{g,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the $R=1000$ replicates.

[3]*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP4 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

Table 6. Classification frequencies for SNP5 association with each pair of QT/time-to-event traits based on the complete joint model and compared models at significance threshold P^*=0.05, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

SNP	Trait pairs	Analysis Model	Mean Bias[1]		Mean Bootstrap SE's and Correlation[2]			Classification frequencies[3] (%) Expected (above) vs Empirical Values			
			$\beta_{g,1}=0$	$\gamma_{g,1}=0$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,1}}}$	$\widehat{\rho_{1,1}}$	Indirect	Direct	Direct & Indirect	**Not Direct & Not Indirect**
								4.75	**4.75**	**0.25**	**90.25**
	HbA1c(*l*=1)/ DR(*k*=1)	JM-cmp	-0.021	<0.001	0.010	0.012	0.001	2.4	5.1	0.4	**92.1**
		JM-mis		0.017		0.015	<0.001	2.4	4.2	0.4	**93.0**
		JM-sep(*l*=1,2; *k*=1)		0.013		0.012	<0.001	2.4	4.4	0.4	**92.8**
		JM-sep(*l*=1; *k*=1)	-0.019	0.013	0.010	0.012	-0.003	2.6	4.4	0.2	**92.8**
		CM-obs	-0.021	0.019	0.010	0.013	0.043	2.4	4.4	0.4	**92.8**
			$\beta_{g,1}=0$	$\gamma_{g,2}\mathbf{=0.4}$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{1,2}}$	Indirect	**Direct**	Direct & Indirect	Not Direct & Not Indirect
								1.44	**67.67**	**3.56**	**27.33**
SNP5 (MAF=20%)	HbA1c(*l*=1)/ DN(*k*=2)	JM-cmp	-0.021	-0.020	0.010	0.025	-0.016	1.1	**64.7**	1.7	32.5
		JM-mis		-0.009		0.029	-0.013	0.8	**62.5**	2.0	34.7
		JM-sep(*l*=1,2; *k*=2)		-0.036		0.026	-0.014	1.2	**61.6**	1.6	35.6
		JM-sep(*l*=1; *k*=2)	-0.019	**0.765**	0.010	0.021	-0.008	0	**97.2**	2.8	0
		CM-obs	-0.021	**0.505**	0.010	0.022	0.017	0	**97.2**	2.8	0
			$\beta_{g,2}\mathbf{=7}$	$\gamma_{g,2}\mathbf{=0.4}$	$\widehat{\sigma_{\beta_{g,2}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{2,2}}$	Indirect	Direct	**Direct & Indirect**	Not Direct & Not Indirect
								28.77	**0**	**71.23**	**0**
	SBP(*l*=2)/ DN(*k*=2)	JM-cmp	0.046	-0.020	0.385	0.025	-0.050	33.6	0	**66.4**	0
		JM-mis		-0.009		0.029	-0.047	35.5	0	**64.5**	0
		JM-sep(*l*=1,2; *k*=2)		-0.036		0.026	-0.047	36.8	0	**63.2**	0
		JM-sep(*l*=2; *k*=2)	0.039	-0.029	0.384	0.025	-0.041	35.1	0	**64.9**	0
		CM-obs	0.046	**0.505**	0.385	0.022	0.280	0	0	**100**	0

[1]Mean Bias in the SNP5 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

[2]Mean Bootstrap SE's, $\sigma_{\beta_{g,l}}$ and $\sigma_{\gamma_{g,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the R=1000 replicates.

[3]*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP5 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

Table 7. Classification frequencies for SNP3 association with each pair of QT/time-to-event traits based on the complete joint model and compared models at significance threshold P^*=0.05, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

SNP	Trait pairs	Analysis Model	Mean Bias[1]		Mean Bootstrap SE's and Correlation[2]			Classification frequencies[3] (%) Expected (above) vs Empirical Values			
			$\beta_{g,1}=0$	$\gamma_{g,1}=0$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,1}}}$	$\widehat{\rho_{1,1}}$	Indirect	Direct	Direct & Indirect	Not Direct & Not Indirect
								4.75	**4.75**	**0.25**	**90.25**
	HbA1c(l=1)/ DR(k=1)	JM-cmp		0.001		0.009	-0.001	4.3	4.5	0.2	**91.0**
		JM-mis	-0.012	0.299	0.006	0.009	-0.004	0.7	86.1	3.8	**9.4**
		JM-sep(l=1,2; k=1)		0.274		0.007	-0.004	0.6	85.8	3.9	**9.7**
		JM-sep(l=1; k=1)	-0.014	0.274	0.006	0.007	-0.003	0.5	85.4	4.3	**9.8**
		CM-obs	-0.012	0.280	0.006	0.008	0.035	0.7	85.5	3.8	**10.0**
			$\beta_{g,1}=0$	$\gamma_{g,2}=0$	$\widehat{\sigma_{\beta_{g,1}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{1,2}}$	Indirect	Direct	Direct & Indirect	Not Direct & Not Indirect
								4.75	**4.75**	**0.25**	**90.25**
SNP3[4] (MAF=40%)	HbA1c(l=1)/ DN(k=2)	JM-cmp		0.004		0.021	-0.012	4.5	3.8	0	**91.7**
		JM-mis	-0.012	0.305	0.006	0.021	-0.016	1.7	55.6	2.8	**39.9**
		JM-sep(l=1,2; k=2)		0.291		0.019	-0.016	1.6	54.8	2.9	**40.7**
		JM-sep(l=1; k=2)	-0.014	0.197	0.006	0.017	0.005	3.2	31.4	1.6	**63.8**
		CM-obs	-0.012	0.228	0.006	0.015	0.019	2.3	46.0	2.2	**49.5**
			$\beta_{g,2}=0$	$\gamma_{g,2}=0$	$\widehat{\sigma_{\beta_{g,2}}}$	$\widehat{\sigma_{\gamma_{g,2}}}$	$\widehat{\rho_{2,2}}$	Indirect	Direct	Direct & Indirect	Not Direct & Not Indirect
								4.75	**4.75**	**0.25**	**90.25**
	SBP(l=2)/ DN(k=2)	JM-cmp		0.004		0.021	-0.017	4.4	3.6	0.2	**91.8**
		JM-mis	0.157	0.305	0.211	0.021	-0.017	1.8	55.6	2.8	**39.8**
		JM-sep(l=1,2; k=2)		0.291		0.019	-0.015	1.8	54.9	2.8	**40.5**
		JM-sep(l=2; k=2)	0.156	0.282	0.212	0.018	-0.009	1.8	53.8	2.6	**41.8**
		CM-obs	0.157	0.228	0.211	0.015	0.316	1.4	45.0	3.2	**50.4**

[1]Mean Bias in the SNP3 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

[2]Mean Bootstrap SE's, $\sigma_{\beta_{g,l}}$ and $\sigma_{\gamma_{g,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the R=1000 replicates.

[3]*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP3 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

[4]All the models, except JM-cmp, do not account for the indirect genetic pathways via the intermediate longitudinal risk factor U. This translates into a large bias in the direct genetic effects $\gamma_{g,k}$ on both time-to-T1DC traits, and increased misclassification rates for SNP3 as a direct association.